Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells by Burton, Peter et al.
 
 
 
 
 
 
 
Burton, P., Adams, D., Abraham, A., Allcock, R., Jiang, Z., McCahill, A., 
Gilmour, J., McAbney, J., Kaupisch, A., Kane, N., Baillie, G.S., Baker, 
A.H., Milligan, G., Houslay, M.D. and Mountford, J.C. (2010) Erythro-9-
(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains 
the expression of pluripotency markers in human embryonic stem cells. 
Biochemical Journal, 432 (3). pp. 575-584. ISSN 0264-6021 
 
http://eprints.gla.ac.uk/40663 
 
Deposited on: 15 February 2011 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
ERYTHRO-9-(2-HYDROXY-3-NONYL)ADENINE (EHNA) BLOCKS 
DIFFERENTIATION  AND MAINTAINS THE EXPRESSION OF PLURIPOTENCY 
MARKERS IN HUMAN EMBRYONIC STEM CELLS  
 
Peter Burton1, David R. Adams2, Achamma Abraham2, Robert W. Allcock2, Zhong Jiang2, 
Angela McCahill1, Jane Gilmour1, John McAbney1, Alexandra Kaupisch1, Nicole M. Kane3, 
George S. Baillie1, Andrew H. Baker3, Graeme Milligan1, Miles D. Houslay1 and Joanne C. 
Mountford1. 
 
From 1Neuroscience and Molecular Pharmacology, Faculty of Biomedical and Life Sciences (FBLS), 
and 3Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, Glasgow 
G12 8QQ, Scotland, UK; 2Department of Chemistry, Heriot-Watt University, Riccarton Campus, 
Edinburgh EH14 4AS, Scotland, UK 
 
Short title: EHNA maintains hESC pluripotency 
 
Address correspondence to Dr J C Mountford, Neuroscience and Molecular Pharmacology, Faculty 
of Biomedical and Life Sciences (FBLS), University of Glasgow, Glasgow G12 8QQ Scotland, UK. 
Email : j.mountford@bio.gla.ac.uk; Phone : +44 141 330 7212 
 
Abbreviations: hESCs, Human embryonic stem cells; EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine; 
bFGF, basic fibroblast growth factor; ADA, Adenosine deaminase; LIF, leukaemia inhibitory factor; 
GSK3β, glycogen synthase kinase 3 beta; PDE, phosphodiesterases; IBMX, isobutylmethylxanthine; 
AICAR, 5-aminoimidazole-4-carboxamide riboside; ABT-702, 4-amino-5-(3-bromophenyl)-7-(6-
morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine; NECA, 5'-N-ethylcarboxamidoadenosine, THEO, 
theophylline; NF, exogenous FGF-free medium; NFE, exogenous FGF-free medium containing 10uM 
EHNA. 
 
 
Keywords: Human embryonic stem cells; EHNA; Differentiation; ell culture; Adenosine Deaminase; 
Fibroblast Growth Factor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Burton et al. 
 
 2 
 
 
 
 
SYNOPSIS 
 
Human embryonic stem cells (hESCs) have enormous potential for use in pharmaceutical 
development and therapeutics, however to realise this potential there is a requirement for simple 
and reproducible cell culture methods that provide adequate numbers of cells of suitable quality.  
We have discovered a novel way of blocking the spontaneous differentiation of hESCs in the 
absence of exogenous cytokines by supplementing feeder-free conditions with erythro-9-(2-
hydroxy-3-nonyl)adenine (EHNA), an established inhibitor of adenosine deaminase (ADA) and 
cyclic nucleotide phosphodiesterase- 2 (PDE2).  hESCs maintained in feeder-free conditions with 
EHNA for more than 10 passages showed no reduction in hESC associated markers including 
NANOG, POU5F1 and SSEA 4 compared to cells maintained in feeder-free conditions 
containing basic fibroblast growth factor (bFGF). Spontaneous differentiation was reversibly 
suppressed by the addition of EHNA, but upon removing EHNA hESC populations underwent 
efficient spontaneous, multi-lineage and directed differentiation. EHNA also acts as a strong 
blocker of directed neuronal differentiation. Chemically distinct inhibitors of ADA and PDE2 
lacked the capacity of EHNA to suppress hESC differentiation, suggesting that the effect is not 
driven by inhibition of either ADA or PDE2. Preliminary structure activity relationship analysis 
found the differentiation blocking properties of EHNA to reside in a pharmacophore comprised 
of a close adenine mimetic with an extended hydrophobic substituent in the 8- or 9-position.  We 
conclude that EHNA and simple 9-alkyladenines can block directed neuronal and spontaneous 
differentiation in the absence of exogenous cytokine addition, and may provide a useful 
replacement for bFGF in large scale or cGMP compliant processes.      
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INTRODUCTION 
 
Human embryonic stem cells (hESCs) can be maintained in an undifferentiated state whilst remaining 
capable of differentiating to all cell types in the body [1, 2], as such, they have huge potential both as 
research tools and for cell therapies. In order to fully exploit this potential we must understand how to 
efficiently maintain hESCs in this self-renewing, pluripotent state.  A large body of evidence indicates 
that the three transcription factors POU5F1, NANOG and SOX2 constitute the core transcriptional 
regulatory circuit that determines the fate of ESCs [3-7]. Expression levels of 
POU5F1/NANOG/SOX2 and their target genes are crucial in imposing stem cell identity and 
controlling differentiation [8], and therefore it is critical for any culture system to maintain appropriate 
expression of this network. Methods to suppress spontaneous differentiation and maintain pluripotent 
hESCs vary greatly and utilise either feeder cells, feeder-conditioned media [9] or different 
combinations of cytokines (including high concentrations of bFGF [10, 11], TGF-
β/NODAL/ACTIVIN signalling molecules [12-14] or bone morphogenic protein (BMP) suppressors 
such as noggin [10, 15]).  
 
Small-molecule chemicals have been used in attempts to replace exogenous cytokines, in particular 
glycogen synthase kinase 3 beta (GSK3β) inhibitors, which stimulate the canonical Wnt/β-catenin 
axis, have been widely used to maintain pluripotency in mESC and in some hESC studies [16].    
Additionally, Ying et al  found that stimulation of cells by exogenous growth factors was not required 
for the maintenance of pluripotency in mouse ESCs, instead suppression of pro-differentiation signals 
– by inhibiting mitogen-activated protein kinase (MAPK), GSK-3β and FGF signaling – was sufficient 
to maintain self-renewal and pluripotency [17].  Thus, rather than using combinations of complex 
growth factors to stimulate self-renewal, protecting the cells from pro-differentiation factors or using 
small-molecule inhibitors of differentiation may provide viable alternatives for the maintenance of 
hESCs.  Given the importance of the core transcriptional network in both maintaining and inducing 
pluripotency, the discovery of small molecules that can maintain the expression of these transcription 
factors, either in the presence of differentiation cues or in the absence of maintenance factors such as 
exogenous FGF, would be a valuable asset to the field and a further step towards unraveling the 
mechanisms of pluripotency.  
 
Cyclic nucleotides are pivotal second messengers that influence a number of critical events including 
cell cycle and differentiation processes. Cyclic nucleotide phosphodiesterases (PDEs) provide the sole 
means of degrading cAMP and cGMP in cells with selective inhibitors shown to provide powerful 
reagents to manipulate specific cellular events and act as therapeutic agents [18]. With this in mind we 
analysed the effect of a range of inhibitors selective for major PDE families on hESC differentiation.  
From this we discovered that erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), an inhibitor of both the 
dual specificity cAMP/cGMP-phosphodiesterase, PDE2 [19] and adenosine deaminase (ADA) [20], 
maintains the expression of hESC pluripotency markers even when cells are cultured under  
differentiating conditions. Moreover, EHNA also prevents differentiation and maintains pluripotency 
when exogenous FGF is removed from a supportive culture system. It thus provides a simple chemical 
entity that is capable of blocking the differentiation of hESCs. 
 
 
 
EXPERIMENTAL  
 
Cell culture and differentiation 
The SA121 hES cell line [21], (Cellartis AB, Dundee, UK) was cultured in feeder-free conditions on 
fibronectin and enzymatically passaged with TrypLE Select (Invitrogen). The fully supportive media 
used to maintain the hESCs was a 1:1 mixture of defined media [22] and conditioned VitrohES 
(VitroLife, Gothenburg, Sweden). VitrohES was conditioned for 24 h on mitotically inactivated mouse 
embryonic fibroblasts (MEF) with no addition of FGF. SA461 hES cells [21] (Cellartis AB) were 
maintained on MEFs and used to test whether EHNA supports the change from feeders to feeder-free 
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culture (Figure 1a). Routine maintenance used bFGF (Invitrogen) at a final concentration of 10 ng/ml 
unless stated otherwise. For passive differentiation cells were passaged onto Matrigel (BD 
Biosciences, Oxford, UK) in fully supportive media, changed to defined medium supplemented with 
experimental components 24 h later and thence changed daily. Cytogenetic analyses confirmed a 
normal karyotype in cells grown in the presence of EHNA for either 10 or 20 passages, or with 
HWC57 or HWC64 for 22 passages (Supplemental Figure 7).  
 
Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) was used at 10 µM unless otherwise stated (Merck 
Chemicals Ltd., Nottingham, UK). Other compounds were purchased from Merck or Sigma-Aldrich 
except BAY-60-7550 (Axxora). A range of EHNA analogues were synthesized; compound structures 
and synthetic procedures are detailed in the Supplemental Chemistry section.  Neuronal differentiation 
was carried out as described previously [23]. Briefly, cells were seeded onto Matrigel (BD 
Biosciences) in 1:1 mix of Advanced D-MEM/F12 containing N2 supplement, and Neurobasal 
supplemented with B27 (all Invitrogen) containing 100 ng/ml mouse recombinant Noggin (R&D 
Systems). Cells were allowed to reach confluence and passaged using collagenase (Invitrogen) after 2 
weeks.  
 
Quantitative PCR 
RNA was extracted and cDNA prepared as previously described [24].  Gene-specific assays were used 
for DNMT3b, KLF4, TEAD4 and POU5F1 (Applied Biosystems (AB)); other primer and probe sets 
were from MWG (Ebersberg, Germany). Biological and technical triplicates were performed for each 
sample, standardised to GAPDH and relative expression values calculated. The human stem cell 
pluripotency Taqman Low Density Array (TLDA) was also used with the 7900HT system (AB).  
 
Immunocytochemistry 
Cells were incubated at 4°C overnight with the following antibodies in 10% goat serum (Sigma-
Aldrich)/PBS: mouse anti-POU5F1 (1:250) (Santa Cruz Biotech., California, USA), rabbit anti-PAX6 
(1:1000) (Millipore Ltd, Herts, UK), mouse anti β-tubulin III (1:1000),  mouse anti-Alpha-feta-protein 
(AFP) (1:400) (Sigma-Aldrich), mouse anti-muscle-specific actin (SMA) (1:50) (Dako, Denmark), 
SSEA1 (1:5), SSEA3 (1:5) (Hybridoma Bank University of Iowa), SSEA4 (1:5) (Hybridoma Bank 
University of Iowa), Tra1-60 (1:200) and Tra1-80 (1:200) (Santa Cruz Biotech.). Secondary antibodies 
were Alexa fluor 555 goat anti-rabbit IgG (1:400) or Alexa fluor 488 goat anti-mouse IgG (1:400) and 
cells were mounted using Prolong Gold containing DAPI (all Invitrogen). All immunofluorescence 
was visualised and captured using Zeiss Axiovision image analysis system. 
 
 
RESULTS 
 
EHNA prevents differentiation and maintains the expression of stem cell markers in the absence of 
exogenous FGF during feeder-free growth. 
The capacity of EHNA to maintain stem cell characteristics and block spontaneous differentiation in 
feeder-free and FGF-free conditions was evaluated by incubating hESCs (Cellartis line SA121) [21] in 
standard feeder-free conditions without exogenous FGF (including conditioned medium made without 
the addition of exogenous FGF) but supplemented with 10 µM EHNA (No FGF/+EHNA medium; 
NFE). Cells were initially seeded from a trypsin passage of a standard, FGF-containing, feeder-free 
culture. Control cells grown without FGF or EHNA (No FGF medium; NF) had reduced stem cell 
marker (NANOG and POU5F1) expression by passage 3 and showed clear differentiated morphology 
by passage 8-10, whereas those grown in the presence of EHNA retained a normal stem cell 
morphology and marker expression to at least passage 10 (Figure 1a) and, in extended experiments, 
for as long as 30 passages. In addition to expressing POU5F1, cells maintained in EHNA for 10 
passages also expressed the cell surface markers SSEA3, SSEA4, TRA-160 and TRA-180, but were 
negative for the differentiation marker SSEA1 (Figure 1b). This marker profile strongly indicated the 
maintenance of a pluripotent phenotype.  
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To determine if prior adaptation to feeder-free conditions is required for EHNA to block the 
differentiation of hESCs in the absence of FGF, a culture of the hESC line SA461 was transferred 
directly from a supportive MEF feeder layer, using manual dissection, to NFE medium. After multiple 
passages the EHNA-containing cultures were still almost 100% positive for POU5F1 whereas 
POU5F1 staining in the cultures grown in NF medium was minimal (Figure 1a). This indicates that 
pre-adaptation to feeder-free conditions was not required for EHNA to block the differentiation of 
hESCs in the absence of FGF and that the effect of EHNA can be seen in a second hESC line..  
 
Real time qRT-PCR analysis showed that at passage 8 in NF medium cells had greatly down-regulated 
the expression of NANOG, POU5F1 and SOX2 in comparison to hESCs grown in standard feeder-
free culture (containing FGF), or to cells grown with EHNA (NFE) (Figure 1c). The NF-cultured cells 
also showed an increase in the expression of a variety of differentiation markers from multiple germ 
layers, particularly those associated with trophoectoderm formation (Supplemental Figure 1). In 
contrast, EHNA (NFE medium) maintained an expression profile similar to that of cells in standard 
feeder-free culture and maintained that pattern for at least 30 passages (Supplemental Figure 2).  
 
Cells maintained in EHNA retain the capacity for in vitro differentiation to all three germ layers. 
It is important that any component of stem cell medium that maintains a pluripotent phenotype does 
not permanently block differentiation of the cells. Therefore, to determine if chronic exposure to 
EHNA still allowed for subsequent differentiation, cells that had been in the EHNA-containing, NFE 
medium for either 10 passages (Figure 2) or >20 passages (Supplemental Figure 3) were allowed to 
differentiate passively. After 4 weeks cells were analysed for PAX6 (ectoderm), alpha-feta protein 
(AFP) (endoderm) and smooth muscle actin (SMA) (mesoderm) in order to detect differentiation to all 
three germ layers. Cells staining positive for three germ layers were readily detected (Figure 2 and 
Supplemental Figure 3). This indicates that, at least in vitro, cells grown in EHNA for over 10 
passages retain functional pluripotency. 
 
In order to understand whether pre-treatment with EHNA has any effect on the dynamics of induced, 
rather than spontaneous, differentiation cells that had been maintained in either EHNA or FGF for five 
passages were transferred into neuronal differentiation conditions [23]. Analysis over the time-course 
demonstrated that expression of PAX6 increased and NANOG decreased similarly in both EHNA-
treated and control cultures, although we did observe that there was slight retardation of the NANOG 
down-regulation in EHNA-maintained cells (Figure 3a-b).  Immunofluorescent staining at the 16 day 
time point also indicated that cells grown previously on EHNA express PAX6 protein and down-
regulate POU5F1 (Figure 3c-d). 
 
EHNA maintains the expression of the core stem cell transcriptional factors in differentiating 
conditions. 
In order to test the direct effect of EHNA in maintaining pluripotent genes and blocking 
differentiation, cells maintained in full feeder-free media were subjected to neuronal differentiation 
conditions in the presence of various doses of EHNA throughout the neuronal differentiation.  As 
illustrated in Figure 4a, EHNA caused a dose-dependent reduction in the proportion of cells staining 
positively for PAX6 with 10 µM EHNA completely eliminating PAX6. Additionally, qRT-PCR 
analysis (Figure 4b-e), showed that the pluripotent markers NANOG, POU5F1 and ZFP42 were all 
maintained by the presence of EHNA. This ability of EHNA to block differentiation was sustained 
over at least 6 weeks of neuronal induction (Figure 4f). Thus, EHNA exerts a dramatic anti-
differentiation effect even in the presence of established differentiating conditions. 
 
EHNA does not suppress hESC differentiation by inhibition of PDE2. 
In order to investigate the basis for EHNA’s anti-differentiation effect, we set out to exploit the 
capacity of EHNA to suppress passive differentiation in defined media. We evaluated the maintenance 
of NANOG and suppression of PAX6 expression as means of defining whether compounds with 
related enzyme-inhibitory activity to EHNA acted similarly on hESCs. In this regard, EHNA is an 
established inhibitor of both adenosine deaminase [20] and PDE2 [19, 25]. In order to evaluate 
whether the effect of EHNA was due to PDE2 inhibition, the specific PDE2 inhibitor, BAY-60-7550 
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(BAY) [26, 27] and the pan-cyclic nucleotide PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX) 
[25], were each separately added to cultures undergoing passive differentiation (as above). In contrast 
to EHNA, treatment with neither BAY nor IBMX maintained stem cell marker expression in 
differentiating conditions (Figure 5a); nor did they inhibit PAX6 induction (Figure 5b). This strongly 
suggests that PDE2 inhibition is not the mechanism whereby EHNA maintains hESC pluripotency.  
 
EHNA does not suppress hESC differentiation by inhibition of adenosine deaminase. 
EHNA is also an established ADA inhibitor and, as such, it causes the accumulation of adenosine and 
deoxyadenosine, resulting in pleiotropic effects upon the cell [20, 28-32]. To determine whether the 
effects of EHNA are mediated by phosphorylated metabolites of adenosine, an adenosine kinase 
inhibitor, ABT-702 (AKI), was used in conjunction with EHNA. After 2 weeks under passive 
differentiation conditions the effects of EHNA were not reduced by the concurrent inhibition of 
adenosine kinase (Figure 5c). Additionally, stimulation of AMPK with 5-aminoimidazole-4-
carboxamide riboside (AICAR) did not mimic the effect of EHNA. Thus, we concluded that 
phosphorylation of adenosine is not necessary for the maintenance of pluripotency markers by EHNA. 
 
Accumulation and export of adenosine and deoxyadenosine can, in principle, lead to activation of the 
adenosine receptors. To investigate whether adenosine receptor activation is responsible for the 
maintenance of hESC pluripotency markers by EHNA, we evaluated whether 5'-N-
ethylcarboxamidoadenosine (NECA), a pan-adenosine receptor agonist, and the non-selective PDE 
inhibitor and adenosine receptor antagonist, theophylline, could ablate the effect of EHNA. Neither 
agent, had any effect on the expression of hESC pluripotency markers in the presence or absence of 
EHNA (Figure 5c).  Similarly, targeting individual adenosine receptor subtypes with specific 
antagonists in addition to EHNA had no effect (Figure 5d). Hence, adenosine receptor activity is 
unlikely to underpin EHNA’s action on hESCs. 
 
To further investigate whether the effect of EHNA might still be driven by ADA inhibition, we 
sourced or synthesised a panel of structurally diverse compounds (Figure 6; Supplemental Figures 4 
and 5) known to possess widely varying degrees of ADA-inhibitory activity. Critically, there was no 
correlation between ADA-inhibitory activity and the capacity of these compounds to maintain 
pluripotency-associated factors and to suppress PAX6 expression. Some compounds with potent 
ADA-inhibitory activity failed to show any EHNA-like effect. Pentostatin, an exceptionally potent 
ADA-inhibitor (Ki = 2.5 pM for ADA) [33], lacked any effect at  concentrations of up to 100 µM even 
in combination with the PDE2 inhibitor, BAY-60-7550 (data not shown). Similarly, erythro-1-(2-
hydroxynonan-3-yl)-1H-imidazole-4-carboxamide (HWC-36), an analogue of EHNA with a truncated 
adenine ring, showed no capacity to maintain NANOG or to suppress PAX6 expression at a 
concentration of 10 µM, despite possessing potent ADA-inhibitory action (Ki = 35 nM vs 7 nM for 
EHNA) [34]. However, a series of 2-alkyl-2H-pyrazolo[3,4-d]pyrimidin-4-amine ADA inhibitors 
described by Da Settimo et al. [35] did exhibit EHNA-like maintenance activity. The octyl, nonyl, 
decyl and undecyl analogues in this series (Figure 6 and Supplemental Figure 4; respectively HWC-
41, HWC-31, HWC-06 and HWC-33), with reported ADA-inhibitory Ki values of 530, 8.1, 0.13 and 
0.47 nM, exhibited pronounced maintenance of the pluripotency marker, NANOG, coupled with a 
suppression of the differentiation marker, PAX6, when tested at 10 µM concentrations. Da Settimo et 
al [35] found the 1-alkyl-substituted isomers of their 2-alkylpyrazolopyrimidine series lacked 
significant ADA-inhibitory activity. However, we found that the octyl- and nonyl- analogues in the 
non-ADA-inhibitory 1-alkylpyrazolopyrimidine series (respectively HWC-40 and HWC-30) retained 
the differentiation-suppressive properties of their 2-alkyl isomers and of EHNA. As shown in Figure 7, 
HWC-30, like HWC-31 and HWC-33, maintained the expression of pluripotency genes whilst 
suppressing PAX6. Collectively these data strongly suggest that the action of EHNA on hESCs is not 
driven by ADA inhibition.  
 
To investigate the possibility that EHNA and other active compounds may act through a protein 
kinase-inhibitory mode, EHNA, HWC-5 and HWC-6 were evaluated using the Protein Kinase Panel 
service of the MRC National Centre for Protein Kinase Screening (University of Dundee, UK). When 
tested at 30 µM, none of these compounds significantly inhibited any of the 80 kinases of the panel 
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(Supplemental Figure 6).  This included GSK-3β[16], a number of ERK/MAPK pathway components 
[36] and FGF-R1 [37], which have all previously been shown to be important in hESC pluripotency. 
 
Structure activity relationships for the differentiation blocking activity of EHNA 
As EHNA did not appear to exert its action on hESCs through inhibition of either PDE2 or ADA, we 
undertook a preliminary structure activity relationship analysis by evaluating a wider set of EHNA 
analogues. The compounds assessed, Figure 6 (and detailed in full in the Supplemental Material) show 
that maintenance of NANOG and suppression of PAX6 requires a compound structure comprising a 
close adenine mimetic with an extended hydrophobic substituent in the 8- or 9-position. We found that 
the EHNA structure could be simplified by removal of the hydroxy group from the nonanol side chain, 
and deoxy-EHNA (HWC-57) retains activity comparable to EHNA itself. As a further step, we 
replaced the branched hydrocarbon chain of the latter compound with a straight chain n-decyl group to 
provide a compound [9-(decan-1-yl)adenine, HWC-64] that also retained the full action of EHNA on 
hESCs. In fact cells grown for 10 passages in FGF-free feeder-free conditions, but supplemented with 
either HWC-57 (10 µM) or HWC-64 (10 µM) show an equivalent morphology (Figure 8a) and gene 
expression pattern (Figure 8b) to those grown in FGF-containing supportive media. Cells without 
either FGF or HWC-57/HWC-64 show a strong differentiated morphology by passage 4 (Figure 8a). 
These data indicate that HWC-57 and HWC-64 are functionally equivalent to EHNA with regard to 
maintaining the markers of pluripotency in the absence of FGF. 
The recently disclosed EHNA-ADA co-crystal structure reveals that its hydroxyl side chain 
contributes an important hydrogen bond to a histidine residue within the catalytic pocket [38]. The 
redundancy of this hydroxyl group in regard to the hESC differentiation blocking properties further 
supports the contention that this activity is not mediated through ADA inhibition. Thus, neither of the 
two established activities of EHNA, namely ADA inhibition and PDE2 inhibition, appear to be 
responsible for the maintenance of hESC pluripotency and suppression of differentiation. This implies 
a novel mechanism of action for which, although currently unidentified, we have provided preliminary 
structure activity relationships (SAR) by studying a range of EHNA analogues.  
DISCUSSION 
 
The regulation and maintenance of pluripotency in hESCs is still far from fully understood and there 
are multiple methods for cultivating hESCs in a pluripotent state. Traditionally hESCs have been 
cultivated on a mouse embryonic feeder layer [2] with further recent advances resulting in feeder-free 
culture systems on extracellular matrix proteins, which may be recombinant or extracted [10-12, 14, 
15]. However, hESCs cultured in these feeder-free systems lack the mainly undefined stimuli from the 
feeder cells that maintain these cells in a self-renewing, pluripotent state and therefore, additional 
recombinant growth factors must be added to replace the contribution of the feeder cells.  The only 
growth factor that has been shown to be essential for the maintenance of pluripotency in the absence 
of feeder-layers or conditioned media is basic FGF (bFGF, FGF-2) [10, 37]. However other factors, 
including TGFβ, are also commonly used to either remove or reduce the need for high concentrations 
of bFGF and/or conditioned media [12-14].  Such recombinant growth factors have a plethora of 
effects and, when considering the potential for using pluripotent cell-derived tissues in the clinic, are 
difficult to obtain from current good manufacturing practice-qualified sources. Simple small molecule 
alternatives to growth factors for maintaining pluripotent hESCs would not only be more amenable to 
current good manufacturing practice-compliant use, but are likely to provide powerful new tools for 
trying to uncover the molecular basis of pluripotency.  
 
We have demonstrated here that the spontaneous differentiation of hESCs in the absence of either 
feeder cells or exogenous cytokines can be blocked by the addition of EHNA. We have also shown 
that EHNA is sufficiently supportive in that cells could be directly switched from feeders into feeder-
free culture without pre-adaptation to feeder-free culture containing exogenous FGF. Importantly, we 
found that chronic EHNA treatment did not ‘lock’ hESCs in an undifferentiated state, as the EHNA-
treated cells were capable of multi-lineage differentiation when EHNA was removed. However, 
suppression of differentiation was sufficiently robust that when cells were switched into neuronal 
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inducing conditions, the continued addition of EHNA blocked PAX6 expression and maintained the 
pluripotent morphology and the markers NANOG, POU5F1 and ZPF42. Furthermore, through our 
structure activity relationship analysis, we discovered that simple 9-alkyladenines, such as HWC-57 
and HWC-64, possess activity comparable to EHNA. These robust, stable compounds are readily 
prepared from commercially available starting materials at low cost in just two synthetic steps, and, as 
such, offer a very attractive alternative to the use of bFGF in large scale applications. 
 
EHNA has a number of reported effects including the inhibition of PDE2 [19], but as we were unable 
mimic the effect of EHNA with either a structurally dissimilar PDE2 specific inhibitor (BAY-60-
7550) [26] or the non-specific cyclic nucleotide PDE inhibitor IBMX [25] we can conclude that  PDE2 
inhibition does not account for the effect of EHNA in hESCs. EHNA has also been reported to reduce 
intracellular trafficking by inhibition of dynein. However, concentrations in the order of 100 µM are 
typically used for inhibiting dynein, because the EC50 value for this lies between 0.23 mM and ~1 mM 
[39, 40]. As we used EHNA at a maximum concentration of 10 µM and see significant effects at 1 
µM, we believe that it is unlikely that EHNA acts through effects on dynein in hESCs. The inhibition 
of ADA by EHNA was a particularly interesting possibility because a deficiency of ADA can cause a 
multitude of effects on the cell including apoptosis, the inhibition of transmethylation and an 
accumulation of adenosine that can subsequently lead to the activation of AMPK and adenosine 
receptors [30, 41]. We therefore investigated whether the ADA-inhibitory activity of EHNA was 
essential to its capacity to block differentiation in hESCs via the accumulation of adenosine and 
autocrine activation of cell-surface receptors, but we could not mimic the effect of EHNA using 
adenosine receptor agonists. Neither could we ablate the effect of EHNA with adenosine receptor 
antagonists. A build up of the phosphorylated metabolites of adenosine was also not responsible for 
the EHNA effect. To further investigate the possibility of ADA inhibition being responsible we used a 
panel of established adenosine deaminase inhibitors that are chemically distinct from EHNA, and 
clearly demonstrated (Figures 6 & 7) that there is no link between the two activities. This leads us to 
believe that EHNA has an unidentified biological activity that is responsible for its ability to prevent 
hESC differentiation.  
 
It is an interesting proposition that EHNA may be able to maintain pluripotent marker expression by 
blocking differentiation. Ying et al. proposed that mESCs actually exist in a basal self-maintaining 
state that can be perpetuated if shielded from differentiation-inducing signals [17]. Unlike mESCs, 
many of the intracellular signalling pathways in hESCs are as yet unidentified. Nevertheless, it is 
probable that they are conceptually similar to mESCs in that pluripotency can be maintained if the 
differentiating signals are removed or blocked.   Our data show that EHNA is an efficient blocker of 
induced neuronal differentiation and of other lineages generated as cells differentiate passively after 
the removal of bFGF. It should also be noted that although feeder-free, the culture system contains a 
conditioned medium component. Therefore, whilst EHNA is an effective replacement for exogenous 
bFGF there may be a combinatorial effect with other conditioning factors in the medium.  
 
It is therefore possible that EHNA might be used to maintain hESCs in a self-renewing ground state, 
regulated by NANOG expression, as has been described for mESCs treated with inhibitors of both 
GSK-3β and MAPK [17, 42]. This hypothesis is supported by our finding that cells maintained in 
EHNA retained the expression of the core transcription factors NANOG, POU5F1 and SOX2 to the 
same degree as those maintained by bFGF, whereas in control cultures from which bFGF was omitted 
these factors were dramatically down-regulated.  Initial reports suggested that GSK3β inhibitors may 
have the same capacity to maintain self-renewal in hESCs as in mESCs [16].  In order to exclude the 
possibility that EHNA was acting by directly inhibiting common protein kinase intracellular signalling 
pathways, we subjected the molecule to a protein kinase screen and found that it did not significantly 
inhibit any of the kinases evaluated, including GSK-3β, a number of ERK/MAPK pathway 
components and the FGF receptor, FGF-R1. 
 
In summary, we have found that a small-molecule additive, EHNA, blocks the differentiation of 
hESCs in the absence of exogenous cytokines or feeder cells and can be used during routine enzymatic 
passage of the cells without the loss of multi-lineage differentiation potential. We have defined a 
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pharmacophore for this action of EHNA, which is independent of its established PDE2- and ADA-
inhibitory activities, and identified simpler compounds that possess comparable activity. The capacity 
of EHNA and these derivates to block hESC differentiation may make them useful tools for the 
manipulation of hESCs and provide an important set of reagents for characterising pathways involved 
in the maintenance of pluripotency or suppression of differentiation in these cells. 
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FIGURE LEGENDS 
 
Figure 1. hESC morphology and marker expression is maintained and differentiation blocked 
by EHNA in the absence of FGF during feeder free growth. (a) (i-ii) SA121 hESCs withdrawn 
from FGF but grown in the presence of EHNA (10 µM) remain undifferentiated. (iv-v) Cells grown in 
the absence of FGF and EHNA show strong differentiated morphology by passage 8 (p8). SA461 hES 
cells taken from feeder supported culture directly into feeder-free conditions remain undifferentiated 
in the presence (iii) but not absence (vi) of EHNA. (b)  Immunofluoresence of SA121 hES cells shows 
the absence of SSEA1 (i) and presence of stem cell markers SSEA3 (ii), SSEA4 (iii), TRA1-60 (iv), 
TRA1-80 (v) and POU5F1 (vi). Specific antibodies are in green and DAPI in blue. Scale bars, 100µm. 
(c) qRT-PCR was used to analyse the samples at p8. Gene expression is relative to expression in 
normal feeder free cells grown with FGF. Student t tests compared data between experimental groups. 
Asterisks indicate that cells treated with EHNA are statistically significant in comparison to cells 
treated with neither EHNA or FGF.  *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
Figure 2. The ability of EHNA to inhibit differentiation is reversible. After growth for 12 passages 
in the presence of EHNA (10 µM) instead of FGF SA121 hESCs were transferred to gelatin and 
differentiated for 4 weeks in 20% fetal calf serum: (a) immunostaining for AFP (green) and DAPI 
(blue), (b) immunostaining for PAX6 (red) and DAPI (blue), (c) immunostaining for smooth muscle 
actin (green) and DAPI (blue). Scale bars, 100µm. 
 
Figure 3. Prior growth in EHNA does not block subsequent differentiation. Neuronal 
differentiations were initiated from SA121 hESCs previously grown with either FGF or EHNA (10 
µM)  for 5 passages: (a) NANOG expression during neuronal differentiation, (b) PAX6 expression 
during neuronal differentiation, (c) immunostaining of neuronal differentiation (day 16) after prior 
growth in EHNA, (d) immunostaining of cells neuronal differentiation (day 16) after prior growth in 
FGF. All images are representative fields stained for POU5F1 (green), Pax6 (red) and DAPI (blue). 
Scale bars, 100µm. 
 
Figure 4. Directed differentiation is inhibited by the presence of EHNA. (a) SA121 cells were 
induced to differentiate towards neural lineages with increasing concentrations of EHNA (0 - 10 µM). 
Immunostaining is of POU5F1 (green), PAX6 (red) and DAPI (blue). Scale bars, 100µm. qRT-PCR 
analysis of (b) Nanog, (c) POUF51, (d) ZFP42, and (e) PAX6  expression was analysed throughout a 
neural differentiation with and without EHNA (10µM) present continually. (f) Expression of NANOG 
and PAX6 was analysed by qRT-PCR at 4 weeks and 6 weeks post neural differentiation induction. 
EHNA was either present throughout (+EHNA; 10 µM) or absent (-EHNA) from the differentiations 
(ND = neural differentiation).  
 
Figure 5. EHNA does not maintain transcription of hESC markers through inhibition of PDE2, 
increased phosphorylated metabolites of adenosine or adenosine receptor activation. SA121 
hESCs underwent passive differentiation for 14 days (with and without compound addition) and were 
subsequently analysed by qRT-PCR.  (a) and (b) Treatment with EHNA and PDE inhibitors. (c)  
Treatment with adenosine kinase inhibitor, AMPK agonist and adenosine receptor agonist and 
antagonist. (d) Treatment with EHNA and inhibitors of each specific adenosine receptor. Data 
represents mean ± SEM from three experiments. For (a) and (b) the value 1 was set to level of 
expression in undifferentiated hESCS whereas in (c) and (d) the value 1 was set to the expression level 
in the untreated control samples. All other values were calculated respectively. EHNA – erythro-9-(2-
hydroxy-3-nonyl)adenine (10 µM); IBMX – 3-isobutyl-1-methylxanthine (100 µM); BAY – BAY-60-
7550 (5 µM); AKI – adenosine kinase inhibitor (ABT-702) (5 µM), AICAR – 5-aminoimidazole-4-
carboxamide-1-ß-D-ribofuranoside (0.5 mM); NECA – adenosine-5’-N-ethylcarboxamide (10 µM), 
THEO – theophylline (10 µM); CPX – 8-cyclopentyl-1,3-dipropylxanthine (10 µM), SCH – SCH 
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58261 (10 µM), M3 – MRS3777 (10 µM), M1 – MRS1754 (10 µM). Student t tests compared data 
between experimental groups. Asterisks indicate that cells treated with EHNA are statistically 
significant in comparison to the untreated control group.  *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
Figure 6. The effect of known ADA  inhibitors and related compounds on the expression of 
NANOG and PAX6 in SA121 hESCs under differentiation conditions. Compounds which 
maintained, after 14 days of differentiation, at least 50% of the level of NANOG-expression in 
comparison to EHNA and those that inhibited the expression of PAX6 to 50% or less than the value of 
the untreated controls were considered to have an EHNA-like effect. Those which had a single effect, 
to these levels, on either PAX6 or NANOG were considered to have a partial-EHNA effect. All 
compounds were tested at 10 µM. All compound structures are defined in the Supplementary Figure 4. 
[44-48]Figure 7. The differentiation blocking effect of EHNA is not associated with adenosine 
deaminase inhibition. SA121 hESCs underwent passive differentiation for 14 days  (with and without 
compound addition) and subsequently analysed by qRT-PCR. Data represents mean ± SEM from three 
experiments. Expression is relative to expression in the untreated control samples. Con – untreated; 
EHNA – erythro-9-(2-hydroxy-3-nonyl)adenine; HWC-57 – deoxy-EHNA; HWC-30 – 2-nonyl-2H-
pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride; HWC-31 – 1-nonyl-1H-pyrazolo[3,4-d]pyrimidin-4-
amine hydrochloride; HWC-33 – 1-undecyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride; 
Pento – pentostatin. All compounds were used at 10 µM. Student t tests compared data between 
experimental groups. Asterisks indicate that cells treated with EHNA are statistically significant in 
comparison to the untreated control group.  *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
 
Figure 8. Standard hESC morphology and expression profile is maintained by HWC-57 and 
HWC-64 in the absence of FGF for up to 10 passages. (a) Phase images of SA121 hESCs grown for 
10 passages in full feeder free media containing FGF (FF), or media containing no FGF (NF), or 
media containing no FGF but supplemented with either 10 µM HWC-57 or HWC-64. (b) Analysis of 
gene expression from cells passaged in the conditions referred to in (a). Gene expression is relative to 
GAPDH. Scale bars, 100µm. 
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Structure Activity Relationship Commentary 
 
In order to define the structural determinants of EHNA’s capacity to suppress hESC differentiation we evaluated a 
range of structurally variant EHNA analogues.  We also included in the test compound set a number of established 
ADA inhibitors with widely different inhibitory potencies in order to probe the potential contribution of ADA inhibition 
to EHNA’s effects on stem cells.   
Removal, replacement or N-substitution of the adenine 6-NH2 group (as in compounds 2-10, Suppl. Fig. B1) 
significantly compromised the EHNA stem cell maintenance capacity.  In principle, this might be consistent with an 
ADA-inhibitory mode of action, since the 6-NH2 group of EHNA makes important contacts within the enzyme’s 
catalytic pocket.  Thus, the recently disclosed EHNA-ADA co-crystal structure (PDB: 2Z7G) reveals that the 6-NH2 
engages Asp296 (a residue that binds the protonated substrate N-7 centre) and networks to Glu217 by two 
hydrogen-bonded bridging water molecules, Suppl. Fig. B2(a)/(b).1 
In contrast to the N-1, N-9 and 6-NH2 centres of EHNA, which are all implicated in binding to ADA, the N-3 position 
makes no contact with the enzyme, Suppl. Fig. B2(b).  Consistent with this, the 3-deaza analogue (11) of EHNA 
reportedly possesses comparable ADA-inhibitory potency to EHNA itself.2  We therefore tested compound 11, but 
found that its stem cell maintenance capacity was much reduced compared to EHNA. 
It has further been shown that good ADA-inhibitory activity is retained in EHNA analogues where the pyrimidine 
ring C-2 and N-3 centres are elided.  Thus, imidazole carboxamides 12 and 13 are effective ADA inhibitors (Ki 368 
nM and 35 nM respectively vs Ki 7 nM for EHNA).3  Co-crystal structures of related compounds (e.g. 14, Suppl. Fig. 
B2(c); PDB: 1NDW)4 show that the imidazole carboxamide closely superimposes onto the EHNA adenine bicycle 
to maintain the same network of interactions with the ADA catalytic pocket.  Compounds 12 and 13 lacked any 
stem cell maintenance effect however.  Given the absence of an effect with these compounds, we examined other 
established ADA inhibitors.  Significantly, pentostatin (deoxycoformycin) (15), a transition state inhibitor of sub-
nanomolar potency,5 also lacked a stem cell maintenance effect.   
In contrast to pentostatin, another established ADA inhibitor, pyrazolopyrimidine 18a (Ki 0.13 nM),6 did exhibit a 
stem cell maintenance effect comparable to EHNA. The ADA inhibitory potency of pyrazolopyrimidines related to 
18a is reportedly strongly dependent on both the length of the hydrocarbon chain and its site of attachment to the 
core heterocycle.  Thus, for a series of 2-alkyl-2H-pyrazolo[3,4-d]pyrimidin-4-amines (16a-19a; Ki 530, 8.1, 0.13 & 
0.47 nM respectively) optimal ADA inhibition was seen with the n-decyl chain and inhibitory potency fell off 
markedly with truncation to n-octyl.6  The isomeric 1-alkyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines (16b-19b) were 
inactive or only very weakly active as ADA inhibitors.7  In the ADA-inhibitory 2-substituted series we found the 
undecyl and nonyl homologues (17a and 19a) to have comparable stem cell maintenance activity to EHNA and 18a, 
though the octyl homologue (16a) was less effective.  Unfortunately, poor solubility characteristics precluded 
assessment of the longer chain compounds (18b and 19b) in the non-ADA-inhibitory 1-substituted series.  The 
shorter chain homologues 16b and 17b were amenable to assessment, however, and compound 17b, with the 
nonyl chain, was found to have a stem cell maintenance effect comparable to that of isomer 17a and to EHNA.  
The octyl homologue (16b) was less active than EHNA, but comparable in activity to isomer 16a. 
Collectively these data strongly suggested that ADA inhibition does not contribute to or is not the sole contributory 
factor responsible for EHNA’s stem cell maintenance properties and that the key structural features required for 
                                                 
1
 T. Kinoshita, T. Tada and I. Nakanishi, Biochem. Biophys. Res. Commun., 2008, 373, 53-57. 
2
 I. Antonini, G. Cristalli, P. Franchetti, M. Grifantini, S. Martelli, G. Lupidi and F. Riva, J. Med. Chem., 1984, 27, 274-278. 
3
 G. Cristalli, A. Eleuteri, P. Franchetti, M. Grifantini, S. Vittori and G. Lupidi, J. Med. Chem., 1991, 34, 1187-1192. 
4
 T. Terasaka, T. Kinoshita, M. Kuno and I. Nakanishi, J. Am. Chem. Soc., 2004, 126, 34-35. 
5
 R. P. Agarwal, T. Spector and R. E. Parks, Jr., Biochem. Pharmacol., 1977, 26, 359-367. 
6
 F. Da Settimo, G. Primofiore, C. La Motta, S. Taliani, F. Simorini, A. M. Marini, L. Mugnaini, A. Lavecchia, E. Novellino, D. Tuscano and C. 
Martini, J Med Chem, 2005, 48, 5162-5174. 
7
 Only compounds 17b-19b were tested in the work described in Ref. 6; the octyl homologue (16b) was not reported. 
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activity are an intact adenine ring (or a close mimetic) together with a long hydrophobic ‘tail’, though the precise 
connection of the latter to the 5-membered ring shows some tolerance.  The presence of the adenine N-7 nitrogen 
appears to be non-critical. 
The activity of the pyrazolopyrimidine compounds (17-19) also suggested that the EHNA side chain hydroxyl might 
be superfluous.  Before assessing this, however, we undertook the preparation and separate evaluation of the two 
erthyro-EHNA enantiomers [(+)-EHNA, (2S,3R)-1 and (–)-EHNA (2R,3S)-1], Suppl. Fig. B1, since the commercially 
supplied EHNA was racemic.  Of these compounds, (2S,3R)-1 is the more potent ADA inhibitor (Ki 0.76 nM vs 62 
nM for the antipode)8 and this isomer was also found to be markedly more effective than the enantiomer [(2R,3S)-1] 
in maintaining stem cell pluripotency.  However, deoxy-EHNA (21), which was prepared in racemic form, did indeed 
show comparable activity to (rac)-EHNA itself.  These data suggest that the hydroxyl in EHNA is merely tolerated in 
(2S,3R)-1 rather than beneficial and that its presence in the enantiomer [(2R,3S)-1] actually compromises activity.  
The deoxy-EHNA analogue (22) with a shortened oct-3-yl side chain also showed similar levels of activity to EHNA 
itself. 
The redundance of the EHNA hydroxyl group for hESC maintenance activity was a significant finding.  This group 
assumes the position of the adenosine substrate 5’-OH and hydrogen bonds to His17 and Asp19 in the ADA 
catalytic pocket, Suppl. Fig. B2(b), thereby making a significant contribution to the binding of the inhibitor.9  The 
                                                 
8
 D. C. Baker and L. D. Hawkins, J Org Chem, 1982, 47, 2179-2184. 
9
 It will be noted that strong ADA-inhibitory activity in the 2-alkyl-2H-pyrazolo[3,4-d]pyrimidin-4-amine series (16a-19a) does not require the 
hydroxylated side chain of EHNA.  This likely reflects the adoption of a distinct but favourable ADA-binding mode by these compounds in 
which the adenine ring N-1 and 6-NH2 centres engage Asp296.  Connection of the long side chain to the pyrazolopyrimidine N-1 position, as 
in the 1-alkyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine series (16b-19b), would preclude adoption of this arrangement, requiring the compounds 
to dock in the EHNA-like mode.  The absence of the branched hydroxylated EHNA side chain (and the adenine ring N-7 centre) severely 
compromises the binding affinity in this mode, however, thus accounting for the absent or very weak ADA-inhibitory activity in this series. 
Suuplementary Figure B1 
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efficacy of deoxy-EHNA in the maintenance of stem cell pluripotency therefore further supports the contention that 
ADA inhibition does not mediate the action of these compounds on stem cells.  Although the EHNA hydroxyl group 
is non-essential for stem cell maintenance activity, the compound’s long hydrophobic side chain was found to be 
critical.  Thus, the two methoxyethoxyethyl-substituted pyrazolopyrimidine isomers (20a/b), with shortened and 
more polar side chains, were significantly less active than EHNA or deoxy-EHNA (21).  Moreover the EHNA 
analogue (23) with a truncated 2-hydroxyhex-3-yl side chain also showed a loss of activity.  Interestingly, the 
activity was not restored by appending a phenyl substituent to the shortened chain of the latter, as in compound 24. 
The size and character of the hydrophobic substituent commensurate with stem cell maintenance activity is 
therefore likely subject to constraints.   
As a further simplification to the structure we assessed 9-(1-decyl)adenine (25) in order to remove the one 
remaining stereogenic centre in the deoxy-EHNA analogues 21/22.  In contrast to EHNA, chemical synthesis of 
compounds 21 and 22 is very readily achieved in simple two-step sequences.  The n-decyl analogue (25) is 
similarly readily prepared but has the advantage of being achiral.  This simple robust compound showed a full stem 
cell maintenance effect comparable with the activity of the isosteric pyrazolopyrimidine (18b) and with that of EHNA 
itself. 
 
Compound Synthesis 
 
General details 
Commercially available reagents from Aldrich and Alfa Aesar chemical companies were generally used as supplied 
without further purification.  Tetrahydrofuran (THF), diethyl ether and toluene were dried by distillation from sodium-
benzophenone ketyl under argon. ‘Light petroleum’ refers to the fraction boiling between 40 °C and 60 °C.  
Anhydrous N,N-dimethylformamide (DMF) was purchased from Aldrich and used as supplied from Sure/SealTM 
bottles. Reactions were routinely carried out under an inert atmosphere of argon or nitrogen.  Analytical thin layer 
chromatography was carried out using aluminium backed plates coated with Merck Kieselgel 60 GF254 (Art. 05554). 
Developed plates were visualized under ultra-violet light (254 nm) and/or alkaline potassium permanganate dip.  
Flash chromatography was performed using DAVISIL® silica (60 Å; 35-70 µM) from Fisher (cat. S/0693/60).  Fully 
characterized compounds were chromatographically homogeneous. 
Supplementary Figure B2: (a) EHNA-ADA co-crystal structure (PDB: 2Z7G).  (b) Detail of EHNA binding mode 
taken from (a); (2S,3R)-EHNA is shown as cyan stick.  (c) Superimposition of imidazole carboxamide 14 (orange 
stick; taken from its ADA co-crystal structure, PDB: 1NDW) onto EHNA (cyan stick). 
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Melting points were determined using a Stuart Scientific SMP10 apparatus and are uncorrected.  IR spectra were 
recorded on a Perkin Elmer 1600 FT IR spectrometer.  Spectra were recorded as potassium bromide discs, as 
solutions in CHCl3, or as films between sodium chloride plates.  Mass spectra were obtained on Kratos Concept IS 
EI (electron impact) and Fisons VG Quattro (electrospray) spectrometers.  1H NMR spectra were recorded at 200 
and 400 MHz on Bruker AC200 and DPX400 spectrometers; 13C NMR spectra were recorded at 50 and 101 MHz 
on the same instruments.  Chemical shifts are recorded in parts per million (δ in ppm) and are referenced against 
solvent signals (δC 77.16 for chloroform and δC 39.52 for methyl sulfoxide) for 13C spectra and solvent residual 
resonances (δH 7.26 for chloroform and δH 2.50 methyl sulfoxide) for 1H spectra.10  Chemical shift values and are 
accurate to ±0.01 ppm and ±0.1 ppm respectively.  J values are given in Hz.  Multiplicity designations used are: s, 
d, t, q, sept and m for singlet, doublet, triplet, quartet, septet and multiplet respectively.  In 13C NMR spectra, 
signals corresponding to CH, CH2, or CH3 groups are assigned from DEPT.  Elemental analyses were carried out 
by the analytical service of the Chemistry Department at Heriot-Watt University using an Exeter CE-440 Elemental 
Analyser. 
The preparation of HWC-04,6 HWC-05,2 HWC-06,6 HWC-07,3 HWC-08,2 HWC-09,2 HWC-10,11 HWC-12,2 HWC-
14,12 HWC-30,6 HWC-31,6 HWC-32,6 HWC-33,6 HWC-36,3 HWC-41,6 HWC-44,13 (+)-EHNA (HWC-46)8 and (–)-
EHNA (HWC-52)8 has been described in the literature.  N6-Methyladenosine (HWC-18) and 2-fluoroadenosine 
(HWC-20) were procured from Aldrich.  Cladribine (HWC-19) and fludarabine (HWC-21) were procured from Sigma. 
racemic erythro-3-(6-mercapto-9H-purin-9-yl)nonan-2-ol (HWC-13) 
A solution of erythro-3-(6-chloro-9H-purin-9-yl)nonan-2-ol11 (208 mg, 0.701 mmol) and thiourea (107 mg, 1.40 
mmol) in ethanol (7 mL) was heated at 85 °C for 2 h .  TLC (9:1 CH2Cl2 / MeOH) indicated consumption of starting 
material (Rf 0.53) and formation of a product component (Rf 0.38) (thiourea Rf 0.21).  The clear reaction mixture 
was cooled and the solvent was evaporated.  The residue was purified was purified chromatographically on a silica 
gel column (25 g).  Gradient elution with CH2Cl2 / MeOH (98:2, 650 mL; 96:4, 200 mL) gave erythro-3-(6-mercapto-
9H-purin-9-yl)nonan-2-ol (134 mg, 0.455 mmol; 65%) as a white powder:  δH (200 MHz; CDCl3/CD3OD) 8.25 (1 H, 
s), 8.12 (1 H, s), 4.47 - 4.35 (1 H, m, chain H-3), 4.07 (1 H, quintet, J 6.1, chain H-2), 2.08 (2 H, q, J 7.3), 1.45 - 
1.12 (8 H, m), 1.10 (3 H, d, J 6.4, chain CH3-1), 0.80 (3 H, approx. t, J 6.8, chain CH3-9);  δC (50 MHz; 
CDCl3/CD3OD) 177.95 (C), 145.74 (CH), 145.45 (C), 143.26 (CH), 136.23 (C), 70.02 (CH), 63.02 (CH), 32.62 (CH2), 
29.72 (2 x CH2), 27.00 (CH2), 23.49 (CH2), 20.34 (CH3), 14.43 (CH3).  erythro-3-(6-Mercapto-9H-purin-9-yl)nonan-
2-ol was evaluated as its hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether 
followed by evaporation: (found: C, 50.27; H, 7.08; N, 16.76. C14H22N4OS/1.1 HCl requires C, 50.27; H, 6.96; N, 
16.75%). 
racemic erythro-3-(6-methoxy-9H-purin-9-yl)nonan-2-ol (HWC-15) 
A solution of erythro-3-(6-chloro-9H-purin-9-yl)nonan-2-ol11 (150 mg, 0.505 mmol) and NaOMe (0.084 mL, 2.02 
mmol) in anhydrous MeOH (10 mL) was heated at 70 °C  for 2 h.  TLC (1:2 light petroleum / EtOAc) indicated the 
transformation of starting material (Rf 0.58) into product (Rf 0.42).  The reaction mixture was cooled, adjusted to pH 
6 with acetic acid and evaporated.  The residual solid was dissolved in water (10 mL) and extracted with CH2Cl2 
(20 mL) and EtOAc (20 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in 
vacuo to give a crude oil that was purified on a silica gel column (20 g). Elution with CH2Cl2 / MeOH (96:4, 150 mL) 
gave erythro-3-(6-methoxy-9H-purin-9-yl)nonan-2-ol (142 mg, 0.486 mmol; 96%) as a pale yellow oil:  δH (200 MHz; 
CDCl3) 8.44 (1 H, s), 7.89 (1 H, s), 4.78 (1 H, br d, J 3.6), 4.38 - 4.19 (2 H, m, chain H-2 and H-3), 4.12 (3 H, s, 
OMe), 2.10 - 1.87 (2 H, m, chain CH2-4), 1.27 (3 H, d, J 6.5, chain CH3-1), 1.24 - 1.00 (8 H, m), 0.77 (3 H, approx. t, 
J 6.6, chain CH3-9);  δC (50 MHz; CDCl3) 161.16 (C), 151.76 (C), 151.64 (CH), 142.44 (CH), 124.24 (C), 69.41 
(CH), 63.30 (CH), 54.42 (OCH3), 31.65 (CH2), 28.96 (CH2), 27.24 (CH2), 26.28 (CH2), 22.63 (CH2), 20.37 (CH3), 
                                                 
10
 H. E. Gottlieb, V. Kotlyar and A. Nudelman, J. Org. Chem., 1997, 62, 7512-7515. 
11
 H. J. Schaeffer and C. F. Schwender, J. Med. Chem., 1974, 17, 6-8. 
12
 L. N. Simon, . R. Mueller and H. Zutter, US Pat., 4451478, 1984. 
13
 E. Abushanab and V. P. Pragnacharyulu Palle, US Pat., 5703084, 1997. 
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14.13 (CH3).  erythro-3-(6-Methoxy-9H-purin-9-yl)nonan-2-ol was evaluated as its hydrochloride salt, formed by 
treatment with a solution of hydrogen chloride in ether followed by evaporation. 
racemic erythro-3-[6-(methylamino)-9H-purin-9-yl]nonan-2-ol (HWC-16) 
A stirred mixture of erythro-3-(6-chloro-9H-purin-9-yl)nonan-2-ol11 (208 mg, 0.701 mmol) and methylamine (33% 
w/w in ethanol; 14.0 mL) was heated at 100 °C in a heavy-walled sealed flask for 17 h.  TLC (9:1 CH2Cl2 / MeOH) 
indicated consumption of starting material (Rf 0.53) and formation of a product component (Rf 0.40).  The reaction 
mixture was evaporated and the residue chromatographed on a silica gel column (25 g).  Gradient elution with 
CH2Cl2 / MeOH (98:2, 600 mL; 96:4, 100 mL) gave erythro-3-[6-(methylamino)-9H-purin-9-yl]nonan-2-ol (191 mg) 
as a pale yellow oil. 1H NMR indicated the presence of minor impurities and the crude material was re-
chromatographed on a silica gel column (20 g). Elution with light petroleum:acetone (2:1, 300 mL) gave erythro-3-
(6-(methylamino)-9H-purin-9-yl)nonan-2-ol (151 mg, 0.518 mmol; 74%):  δH (200 MHz; CDCl3) 8.32 (1 H, s), 7.67 (1 
H, s), 6.17 (1 H, br q, NH), 5.48 (1 H, br s, NH), 4.25 - 4.13 (2 H, m, chain H-2 and H-3), 3.18 (3 H, br d, NMe), 2.09 
- 1.77 (2 H, m, chain CH2-4), 1.25 (3 H, d, J 6.5, chain CH3-1), 1.23 - 1.04 (8 H, m), 0.79 (3 H, approx. t, J 6.5, 
chain CH3-9);  δC (50 MHz; CDCl3) 155.83 (C), 152.67 (C), 152.67 (CH), 140.03 (CH), 124.04 (C), 69.78 (CH), 
63.93 (CH), 31.72 (CH2), 29.01 (CH2), ~28 (br, NMe), 27.43 (CH2), 26.47 (CH2), 22.66 (CH2), 20.49 (CH3), 14.16 
(CH3). 
racemic erythro-3-[6-(dimethylamino)-9H-purin-9-yl]nonan-2-ol (HWC-17) 
Dimethylamine hydrochloride (3.0 g, 36.8 mmol) was dissolved in water (9 mL) and cooled in an ice-bath.  Sodium 
hydroxide (1.47 g, 36.8 mmol) was added in portions with stirring. The resulting aqueous dimethylamine solution 
was added to a solution of erythro-3-(6-chloro-9H-purin-9-yl)nonan-2-ol11 (215 mg, 0.724 mmol) in ethanol (5 mL) 
and the mixture heated at 100 °C for 17 h in a heav y-walled sealed flask.  TLC (1:1 light petroleum / EtOAc) 
indicated transformation of starting material (Rf 0.28) into product (Rf 0.15).  The reaction mixture was concentrated 
in vacuo; the residue diluted with water (10 mL) and extracted with EtOAc (50 mL) and CH2Cl2 (2 × 15 mL).  The 
combined extract was dried over Na2SO4, filtered and evaporated to give an oily residue that was chromatographed 
on a silica gel column (25 g). Elution with CH2Cl2 / MeOH (96:4, 250 mL) gave erythro-3-[6-(dimethylamino)-9H-
purin-9-yl]nonan-2-ol (220 mg, 0.720 mmol; 99%) as a colourless oil:  δH (200 MHz; CDCl3) 8.23 (1 H, s), 7.63 (1 H, 
s), 5.65 (1 H, br s), 4.29 - 4.11 (2 H, m, chain H-2 and H-3), 3.51 (6 H, br s), 2.12 - 1.75 (2 H, m, chain CH2-4), 1.25 
(3 H, d, J 6.5, chain CH3-1), 1.22 - 1.00 (8 H, m), 0.79 (3 H, approx. t, J 6.5, chain CH3-9);  δC (50 MHz; CDCl3) 
155.23 (C), 151.71 (CH), 150.06 (C), 138.78 (CH), 120.88 (C), 69.89 (CH), 64.20 (CH), 38.79 (br, 2 x CH3), 31.74 
(CH2), 29.05 (CH2), 27.16 (CH2), 26.53 (CH2), 22.69 (CH2), 20.54 (CH3), 14.18 (CH3).  erythro-3-[6-
(Dimethylamino)-9H-purin-9-yl]nonan-2-ol was evaluated as its hydrochloride salt, formed by treatment with a 
solution of hydrogen chloride in ether followed by evaporation: (found: C, 50.54; H, 8.07; N, 18.09. C16H27N5O/2.05 
HCl requires C, 50.55; H, 7.70; N, 18.42%). 
racemic erythro-3-(6-amino-8-methyl-9H-purin-9-yl)nonan-2-ol (HWC-24) 
racemic erythro-3-(6-Chloro-8-methyl-9H-purin-9-yl)nonan-2-ol 
Ethanesulfonic acid (8.00 µL, 0.098 mmol) was added to a stirred solution of erythro-3-(5-amino-6-chloropyrimidin-
4-ylamino)nonan-2-ol11 (192 mg, 0.669 mmol) in triethyl orthoacetate (3.0 mL) and CHCl3 (1.0 mL).  The reaction 
mixture was stirred at room temperature for 1 h.  TLC (1:1 light petroleum / EtOAc) indicated consumption of 
starting material (Rf 0.35, staining yellow in air) and formation of a product component (Rf 0.30) and a minor 
component (Rf 0.56). The reaction mixture was diluted with CH2Cl2 (50 mL) and washed with saturated sodium 
bicarbonate solution (3 x 10 mL).  The organic layer was dried over Na2SO4, filtered and concentrated in vacuo to 
give a pale yellow oily which was chromatographed on a silica gel column (25 g).  Gradient elution with light 
petroleum / EtOAc (3:1, 400 mL; 2:1, 300 mL; 1:1, 200 mL) gave erythro-3-(6-chloro-8-methyl-9H-purin-9-yl)nonan-
2-ol (Rf 0.30) (102 mg, 0.328 mmol; 49%) as a dense colourless oil:  δH (200 MHz; CDCl3) 8.57 (1 H, s), 4.66 (1 H, 
s), 4.45 - 4.30 (1 H, m), 4.18 - 4.04 (1 H, m), 2.64 (3 H, s), 2.40 - 1.91 (2 H, m, chain CH2-4), 1.18 (3 H, d, J 6.4, 
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chain CH3-1), 1.15 - 0.98 (8 H, m), 0.74 (3 H, approx. t, J 6.5, chain CH3-9);  δC (50 MHz; CDCl3) 156.04 (C), 
152.55 (C), 150.40 (CH), 149.66 (C), 131.23 (C), 69.40 (CH), 64.78 (CH), 31.63 (CH2), 29.08 (CH2), 27.72 (CH2), 
26.58 (CH2), 22.57 (CH2), 21.26 (CH3), 15.60 (CH3), 14.07 (CH3). 
racemic erythro-3-(6-Amino-8-methyl-9H-purin-9-yl)nonan-2-ol (HWC-24) 
A solution of erythro-3-(6-chloro-8-methyl-9H-purin-9-yl)nonan-2-ol (97 mg, 0.31 mmol) in ammonia 7 N in MeOH 
(10 mL) was stirred at 120 °C in a heavy-walled sea led tube for 18 h.  TLC (95:5 CH2Cl2 / MeOH) indicated the 
starting material (Rf 0.44) was transformed into a minor product (Rf 0.26) and a major product at (Rf 0.12).  The 
reaction mixture was concentrated in vacuo to give a light brown residue that was chromatographed on a silica gel 
column (20 g).  Gradient elution with CH2Cl2 / MeOH (98:2, 200 mL; 96:4, 200 mL) gave erythro-3-(6-amino-8-
methyl-9H-purin-9-yl)nonan-2-ol (Rf 0.12) (81 mg, 0.278 mmol; 89%) as a white solid:  δH (200 MHz; CDCl3) 8.14 (1 
H, s, H-2), 6.25 (1 H, br s, OH), 4.26 (1 H, qd, J 6.5 and 3.0, chain H-2), 3.97 (1 H, dt, J 11.1 and 3.0, chain H-3), 
2.51 (3 H, s, 8-Me), 2.30 - 1.81 (2 H, m, chain CH2-4), 1.21 (3 H, d, J 6.5, chain CH3-1), 1.22 - 1.06 (8 H, m), 0.76 
(3 H, approx. t, J 6.5, chain CH3-9);  δC (50 MHz; CDCl3) 154.78 (C), 154.73 (C), 151.22 (CH), 150.02 (C), 149.85 
(C), 69.35 (CH), 64.19 (CH), 31.59 (CH2), 29.08 (CH2), 27.37 (CH2), 26.55 (CH2), 22.52 (CH2), 21.02 (CH3), 14.91 
(CH3), 13.98 (CH3).  The minor product component (Rf 0.26; ~10 mg) was identified as 3-(6-methoxy-8-methyl-9H-
purin-9-yl)nonan-2-ol: δH (200 MHz; CDCl3) 8.39 (1 H, s, H-2), 5.67 (1 H, br s, OH), 4.32 (1 H, qd, J 6.5 and 2.3, 
chain H-2), 4.16 (3 H, s, OMe), 4.06 (1 H, dt, J 11.1 and 2.7, chain H-3), 2.59 (3 H, s, 8-Me), 2.31 - 1.84 (2 H, m, 
chain CH2-4), 1.27 (3 H, d, J 6.4, chain CH3-1), 1.22 - 1.06 (8 H, m), 0.76 (3 H, approx. t, J 6.8, chain CH3-9); δC 
(50 MHz; CDCl3) 160.49 (C), 152.44 (C), 152.05 (C), 150.49 (CH), 121.00 (C), 69.92 (CH), 64.46 (CH), 54.37 
(OCH3), 31.70 (CH2), 29.23 (CH2), 27.39 (CH2), 26.65 (CH2), 22.66 (CH2), 21.43 (CH3), 15.22 (CH3), 14.14 (CH3).  
erythro-3-(6-Amino-8-methyl-9H-purin-9-yl)nonan-2-ol was evaluated as its hydrochloride salt, formed by treatment 
with a solution of hydrogen chloride in ether followed by evaporation. 
racemic erythro-3-[6-(methylthio)-9H-purin-9-yl]nonan-2-ol (HWC-25) 
Sodium thiomethoxide (71 mg, 1.0 mmol) was added to a stirred solution of erythro-3-(6-chloro-9H-purin-9-
yl)nonan-2-ol11 (150 mg, 0.505 mmol) in a mixture of DMF (3 mL) and water (1 mL) at 0 °C.  The mixture was 
allowed to attain room temperature and stirred for 3 h.  TLC (9:1 CH2Cl2 / MeOH) indicated consumption of starting 
material (Rf 0.53) and formation of product (Rf 0.60).  The reaction mixture was diluted with EtOAc (50 mL) and 
then washed successively with water (15 mL), saturated sodium bicarbonate solution (15 mL) and brine (15 mL).  
The organic phase was dried over Na2SO4, filtered and evaporated to give a dense colourless oil that was 
chromatographed on a silica gel column (10 g).  Gradient elution with CH2Cl2 / MeOH (99:1, 100 mL; 98:2, 100 mL) 
gave partially purified product (152 mg) that was re-chromatographed on a silica gel column (10 g). Gradient 
elution with CH2Cl2 / MeOH (99:1, 100 mL, 98:2, 100 mL) gave erythro-3-[6-(methylthio)-9H-purin-9-yl]nonan-2-ol 
(146 mg, 0.473 mmol; 94%): δH (200 MHz; CDCl3) 8.62 (1 H, s), 7.98 (1 H, s), 4.72 (1 H, br d, J 4.1, OH), 4.38 (1 H, 
dt, J 10.7 and 3.5, chain H-3), 4.22 (1 H, ~qt, J 6.4 and 3.3, chain H-2), 2.62 (3 H, s, SMe), 2.17 - 1.85 (2 H, m, 
chain CH2-4), 1.25 (3 H, d, J 6.5, chain CH3-1), 1.20 - 0.95 (8 H, m), 0.76 (3 H, approx. t, J 6.5, chain CH3-9); δC 
(50 MHz; CDCl3) 161.84 (C), 151.47 (CH), 148.06 (C), 142.72 (CH), 131.42 (C), 69.28 (CH), 62.70 (CH), 31.58 
(CH2), 28.90 (CH2), 27.30 (CH2), 26.17 (CH2), 22.56 (CH2), 20.34 (CH3), 14.06 (CH3), 11.86 (CH3).  
racemic erythro-3-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)nonan-2-ol (HWC-26) 
Sodium nitrite (64 mg, 0.93 mmol) in water (3 mL) was added slowly to a mixture of erythro-3-(5-amino-6-
chloropyrimidin-4-ylamino)nonan-2-ol11 (220 mg, 0.767 mmol) in ethanol (5 mL) and hydrochloric acid 1 M (2 mL) 
at 0 °C.  The mixture was stirred at  0 °C for 30 m inutes, treated with conc. ammonium hydroxide (5.0 mL) and 
refluxed for 30 minutes.  The water was reduced by azeotropic distillation of the reaction mixture with toluene and 
ethanol to give a crude solid (300 mg) that was chromatographed on a silica gel column (20 g).  Elution with CH2Cl2 
/ MeOH (95:5, 200 mL) gave erythro-3-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)nonan-2-ol (185 mg, 0.665 
mmol; 87%) as a pale yellow solid: δH (400 MHz; CDCl3) 8.45 (1 H, s), 7.20 (2 H, br s, NH2), 4.89 (1 H, dt, J 11.2 
and 3.3, chain H-3), 4.58 (1 H, br d, J 2.2, OH), 4.37 - 4.30 (1 H, m, chain H-2), 2.32 - 2.19 (1 H, m), 2.08 - 1.99 (1 
Burton et al  Supplementary Material 
 B7 Chemistry 
H, m), 1.32 (3 H, d, J 6.4, chain CH3-1), 1.30 - 1.13 (7 H, m), 1.05 - 0.93 (1 H, m), 0.84 (3 H, approx. t, J 6.5, chain 
CH3-9); δC (101 MHz; CDCl3) 156.26 (C), 156.25 (CH), 149.16 (C), 124.61 (C), 69.57 (CH), 66.23 (CH), 31.49 
(CH2), 28.74 (CH2), 28.02 (CH2), 26.05 (CH2), 22.46 (CH2), 19.75 (CH3), 13.97 (CH3). erythro-3-(7-amino-3H-
[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)nonan-2-ol was evaluated as its hydrochloride salt, formed by treatment with a 
solution of hydrogen chloride in ether followed by evaporation: (found: C, 47.60; H, 7.62; N, 25.54. C13H22N6O /1.0 
HCl/0.75 H2O requires C, 47.56; H, 7.52; N, 25.60%). 
racemic erythro-3-(6-hydrazinyl-9H-purin-9-yl)nonan-2-ol (HWC-27) 
A mixture of erythro-3-(6-chloro-9H-purin-9-yl)nonan-2-ol11 (210 mg, 0.708 mmol) and hydrazine hydrate (0.344 mL) 
in ethanol (7.0 mL) was refluxed at 85 °C for 20 h.  TLC (9:1 CH2Cl2 / MeOH) indicated consumption of starting 
material (Rf 0.53) and formation of a product component (Rf 0.20, air sensitive).  The reaction mixture was 
evaporated and the residue was chromatographed on a silica gel column (25 g).  Gradient elution with CH2Cl2 / 
MeOH (98:2, 200 mL; 95:5, 200 mL; 9:1, 100 mL) gave erythro-3-(6-hydrazinyl-9H-purin-9-yl)nonan-2-ol (137 mg, 
0.469 mmol; 66%) as a white solid:  δH (400 MHz; DMSO-d6) 8.87 (1 H, br s, NH), 8.22 (1 H, br s), 8.16 (1 H, s), 
5.15 (1 H, d, J 5.5, OH), 4.57 (2 H, br s, NH2), 4.28 - 4.15 (1 H, m, chain H-3), 4.24 (1 H, ~sextet, J 6.2, chain H-3), 
2.07 - 2.02 (2 H, m, chain CH2-4), 1.22 - 1.02 (8 H, m), 0.89 (3 H, d, J 6.3, chain CH3-1), 0.78 (3 H, approx. t, J 6.5, 
chain CH3-9); δC (101 MHz; DMSO-d6) 155.91 (C), 152.44 (CH), 149.69 (C), 140.30 (CH), 118.25 (C), 68.42 (CH), 
61.28 (CH), 31.42 (CH2), 29.21 (CH2), 28.49 (CH2), 25.92 (CH2), 22.33 (CH2), 20.86 (CH3), 14.27 (CH3).  
1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine (HWC-34) and  
2-[2-(2-methoxyethoxy)ethyl]-2H-pyrazolo[3,4-d]pyrimidin-4-amine (HWC-35) 
3-Amino-1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazole-4-carbonitrile & 5-amino-1-[2-(2-methoxyethoxy)ethyl]-
1H-pyrazole-4-carbonitrile 
1-Bromo-2-(2-methoxyethoxy)ethane (753 µL, 5.59 mmol) was added dropwise to a suspension of 3-amino-1H-
pyrazole-4-carbonitrile (504 mg, 4.66 mmol) and anhydrous potassium carbonate (0.773 g, 5.59 mmol) in DMF (5.0 
mL) and the reaction mixture was stirred at 50 °C f or 20 h.  TLC (CH2Cl2/MeOH, 9:1) indicated consumption of 
starting material 3-amino-1H-pyrazole-4-carbonitrile (Rf 0.29) and formation of two product components (Rf 0.47 
and 0.42).  After cooling, the inorganic material was filtered off and the solution was evaporated to dryness under 
reduced pressure.  The residue was chromatographed on a silica gel column (25 g).  Gradient elution with CH2Cl2 / 
MeOH (99:1, 100 mL; 98:2, 200 mL; 95:5, 200 mL) gave 5-amino-1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazole-4-
carbonitrile (225 mg, 1.07 mmol; 23%) (Rf 0.47), 3-amino-1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazole-4-carbonitrile 
(329 mg, 1.56 mmol; 34%) (Rf 0.42) and a 1.8:1 mixture of the two isomers (424 mg; 43%) as colourless oils. 5-
Amino-1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazole-4-carbonitrile:  δH (400 MHz; CDCl3) 7.41 (1 H, s, pyrazole H), 
4.98 (2 H, br s, NH2), 4.15 - 4.11 (2 H, m), 3.78 - 3.75 (2 H, m), 3.60 - 3.56 (2 H, m), 3.49 - 3.46 (2 H, m), 3.32 (3 H, 
s);  δC (101 MHz; CDCl3) 151.93 (C), 140.09 (CH), 114.61 (C), 76.20 (C), 71.43 (CH2), 70.85 (CH2), 70.29 (CH2), 
58.87 (OCH3), 49.60 (NCH2). 3-Amino-1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazole-4-carbonitrile:  δH (400 MHz; 
CDCl3) 7.66 (1 H, s, pyrazole H), 4.18 (2 H, br s, NH2), 4.12 - 4.09 (2 H, m), 3.80 - 3.7 (2 H, m), 3.60 - 3.57 (2 H, m), 
3.52 - 3.49 (2 H, m), 3.38 (3 H, s);  δC (101 MHz; CDCl3) 156.65 (C), 135.38 (CH), 113.82 (C), 78.89 (C), 71.74 
(CH2), 70.56 (CH2), 68.83 (CH2), 59.02 (OCH3), 52.46 49.60 (NCH2). 
1-[2-(2-Methoxyethoxy)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine (HWC-34) 
Formamide (0.500 mL, 12.5 mmol) was added to 5-amino-1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazole-4-carbonitrile 
(196 mg, 0.932 mmol) and the reaction mixture was heated at 210 °C for 1.5 h.  TLC (9:1 CH 2Cl2 / MeOH) 
indicated consumption of starting material (Rf 0.47) and formation of a product component (Rf 0.35) with some 
trace impurities.  After cooling, the brown solution was diluted with MeOH, mixed with silica gel and allowed to 
evaporate for 18 h.  The crude sample (dry loaded) was chromatographed on a silica gel column (20 g).  Gradient 
elution with CH2Cl2 / MeOH (98:2, 250 mL; 95:5, 250 mL) gave an oil (600 mg). The partially purified oil was 
dissolved in EtOAc (100 mL) and washed with water (3 x 15). The organic phase was dried over Na2SO4, filtered 
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and concentrated in vacuo to give 1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine (165 mg, 
0.695 mmol; 75%) as a white solid:  δH (400 MHz; CDCl3) 8.34 (1 H, s), 8.10 (1 H, s), 6.69 (2 H, br s, NH2), 4.61 (2 
H, t, J 5.7), 4.00 (2 H, t, J 5.7), 3.65 - 3.60 (2 H, m), 3.51 - 3.46 (2 H, m), 3.31 (3 H, s, OMe);  δC (101 MHz; CDCl3) 
156.36 (C), 153.21 (CH), 153.14 (C), 132.14 (CH), 100.36 (C), 71.77 (CH2), 70.15 (CH2), 69.02 (CH2), 58.89 (OMe), 
46.90 (NCH2).  
2-[2-(2-Methoxyethoxy)ethyl]-2H-pyrazolo[3,4-d]pyrimidin-4-amine (HWC-35) 
Formamide (0.700 mL, 17.6 mmol) was added to 3-amino-1-[2-(2-methoxyethoxy)ethyl]-1H-pyrazole-4-carbonitrile 
(304 mg, 1.45 mmol) and the reaction mixture was heated at 210 °C for 1.5 h.  TLC (9:1 CH 2Cl2 / MeOH) indicated 
consumption of starting material (Rf 0.42) and formation of a product component (Rf 0.25) with some trace 
impurities.  After cooling, the brown mixture was diluted with MeOH, mixed with silica gel and allowed to evaporate 
at room temperature for 18 h.  The crude material (dry loaded) was chromatographed on a silica gel column (20 g).  
Gradient elution with CH2Cl2 / MeOH (98:2, 250 mL; 95:5, 250 mL; 9:1, 250 mL) gave 2-[2-(2-
methoxyethoxy)ethyl]-2H-pyrazolo[3,4-d]pyrimidin-4-amine (196 mg, 0.826 mmol; 57%) as a light brown solid:  δH 
(400 MHz; CDCl3/CD3OD) 8.26 (1 H, s), 8.23 (1 H, s), 4.49 - 4.45 (2 H, m), 3.92 - 3.88 (2 H, m), 3.55 - 3.52 (2 H, 
m), 3.47 - 3.44 (2 H, m), 3.29 (3 H, s, OMe);  δC (101 MHz; CDCl3/CD3OD) 159.36 (C), 159.18 (C), 155.51 (CH), 
125.87 (CH), 101.64 (C), 71.53 (CH2), 70.11 (CH2), 69.00 (CH2), 58.67 (OMe), 53.74 (NCH2).  
1-octyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride (HWC-40) and 
2-octyl-2H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride (HWC-41)  
3-Amino-1-octyl-1H-pyrazole-4-carbonitrile and 5-amino-1-octyl-1H-pyrazole-4-carbonitrile 
1-Bromooctane (1.04 mL, 5.99 mmol) was added dropwise to a suspension of 3-amino-1H-pyrazole-4-carbonitrile 
(540 mg, 5.00 mmol) and anhydrous potassium carbonate (828 mg, 5.99 mmol) in diemtheylformamide (5.0 mL) at 
room temperature and the reaction mixture was stirred at 50 °C for 18 h. TLC (2:1 light petroleum / Et OAc) 
indicated consumption of starting material 3-amino-1H-pyrazole-4-carbonitrile (Rf 0.03) and formation of product (Rf 
0.30).  After cooling, the inorganic material was filtered off and the solution was evaporated to dryness under 
reduced pressure.  The residue was chromatographed on a silica gel column (20 g).  Gradient elution with light 
petroleum / EtOAc (7:1, 200 mL; 3:1, 200; 1:1, 100 mL) gave a 2.4:1 mixture of 3-amino-1-octyl-1H-pyrazole-4-
carbonitrile and 5-amino-1-octyl-1H-pyrazole-4-carbonitrile (684 mg, 3.11 mmol; 63%). Major product:  δH (400 
MHz; CDCl3) 7.49 (1 H, s), 4.29 (2 H, br s), 3.90 (2 H, t, J 7.2), 1.82 (2 H, quintet, J 7.1), 1.30 - 1.17 (10 H, m), 0.85 
(3 H, approx. t, J 6.6); δC (101 MHz; CDCl3) 156.69 (C), 133.76 (CH), 113.84 (C), 78.37 (C) 52.68 (CH2), 31.70 
(CH2), 29.57 (CH2), 29.06 (CH2), 28.98 (CH2), 26.41 (CH2), 22.58 (CH2), 14.05 (CH3). 
1-Octyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride (HWC-40) and 2-octyl-2H-pyrazolo[3,4-
d]pyrimidin-4-amine hydrochloride (HWC-41) 
Formamide (0.800 mL, 20.1 mmol) was added to a mixture of 5-amino-1-octyl-1H-pyrazole-4-carbonitrile and 3-
amino-1-octyl-1H-pyrazole-4-carbonitrile (1:2.35; 618 mg, 2.81 mmol) and the reaction mixture was heated at 210 
°C for 1 h.  TLC (9:1 CH 2Cl2 / MeOH) indicated consumption of starting materials (Rf 0.65) and formation of two 
product components (Rf 0.31 & 0.24) with some trace impurities.  After cooling, water was added to the brown 
reaction mixture and the separated solid was collected by filtration, washing with water, and dried over P2O5 in 
vacuo.  The crude material was chromatographed on a silica gel column (25 g).  Gradient elution with CH2Cl2 / 
MeOH (98:2, 400 mL; 95:5, 250 mL; 9:1, 175 mL) gave partially purified 1-octyl-1H-pyrazolo[3,4-d]pyrimidin-4-
amine (106 mg) and pure 2-octyl-2H-pyrazolo[3,4-d]pyrimidin-4-amine (365 mg, 1.48 mmol) (Rf 0.24). The partially 
purified 1-octyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (Rf 0.31) was re-chromatographed on a silica gel column (20 
g). Elution with light petroleum / EtOAc (1:1.5, 400 mL) gave 1-octyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (91 mg, 
0.37 mmol).  
1-Octyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine:  δH (400 MHz; CDCl3) 8.39 (1 H, s), 7.92 (1 H, s), 6.14 (2 H, br s, 
NH2), 4.40 (2 H, t, J 7.2), 1.93 (2 H, quintet, J 7.3), 1.33 - 1.23 (10 H, m), 0.86 (3 H, approx. t, J 6.9); δC (101 MHz; 
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CDCl3) 157.69 (C), 155.52 (CH), 153.23 (C), 130.23 (CH), 100.58 (C), 47.33 (CH2), 31.71 (CH2), 29.65 (CH2), 
29.09 (2 x CH2), 26.64 (CH2), 22.58 (CH2), 14.05 (CH3). 1-Octyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine was 
evaluated as its hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether followed by 
evaporation: (found: C, 53.84; H, 7.95; N, 24.68. C13H21N5/1.12 HCl requires C, 54.18; H, 7.74; N, 24.30%). 
2-Octyl-2H-pyrazolo[3,4-d]pyrimidin-4-amine:  δH (400 MHz; CDCl3/CD3OD) 8.29 (1 H, s), 8.18 (1 H, s), 4.26 (2 H, t, 
J 7.2), 1.97 - 1.87 (2 H, m), 1.27 - 1.18 (10 H, m), 0.82 (3 H, approx. t, J 6.9); δC (101 MHz; CDCl3/CD3OD) 159.67 
(C), 159.36 (C), 155.90 (CH), 124.09 (CH), 101.61 (C), 54.00 (CH2), 31.65 (CH2), 30.13 (CH2), 29.01 (CH2), 28.97 
(CH2), 26.48 (CH2), 22.51 (CH2), 13.95 (CH3). 2-Octyl-2H-pyrazolo[3,4-d]pyrimidin-4-amine was evaluated as its 
hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether followed by evaporation: 
(found: C, 48.82; H, 7.46; N, 22.20. C13H21N5/1.95 HCl requires C, 49.03; H, 7.26; N, 21.99%). 
(2S,3R)-3-(6-amino-9H-purin-9-yl)-5-phenylpentan-2-ol hydrochloride (HWC-44) 
(S,E)-4-(tert-Butyldimethylsilyloxy)-1-phenylpent-1-en-3-one 
n-Butyllithium (2.5 M in hexane; 8.81 mL, 22.0 mmol) was added dropwise to a solution of (S)-dimethyl 3-(tert-
butyldimethylsilyloxy)-2-oxobutylphosphonate14 (6.84 g, 22.0 mmol) in THF (100 mL) at -78 °C.  Af ter 25 minutes, 
benzaldehyde (2.03 mL, 20.0 mmol) was added and the reaction mixture was slowly allowed to attain to room 
temperature and stirred for 18 h.  TLC (light petroleum / EtOAc 95:5) indicated the presence of the starting 
materials benzaldehyde (Rf 0.31) and phosphonate (Rf 0.05) and a new component (Rf 0.44).  The reaction mixture 
was warmed to 40 °C for 16 h after which period TLC  indicated the complete consumption of starting material.  The 
reaction mixture was quenched by the slow addition of saturated sodium bicarbonate solution (50 mL) and 
extracted with CH2Cl2 (150 mL).  The organic extract was washed with brine (2 x 30 mL), dried with Na2SO4, 
filtered and evaporated to give a crude material (6.08 g) as a pale yellow oil.  The crude material was 
chromatographed on a silica gel column (60 g).  Elution with light petroleum / EtOAc (95:5, 600 mL) gave (S,E)-4-
(tert-butyldimethylsilyloxy)-1-phenylpent-1-en-3-one (5.03 g, 17.3 mmol; 86%):  δH (200 MHz; CDCl3) 7.71 (1 H, d, 
J 16.1), 7.60 - 7.53 (2 H, m), 7.41 - 7.35 (3 H, m), 7.27 (1 H, d, J 16.1), 4.32 (1 H, q, J 6.8), 1.35 (3 H, d, J 6.8), 
0.92 (9 H, s), 0.08 (3 H, s), 0.07 (3 H, s); δC (50 MHz; CDCl3) 202.37 (C=O), 144.05 (CH), 135.03 (C), 130.71 (CH), 
129.13 (2 x CH), 128.63 (2 x CH), 120.33 (CH), 74.88 (CH), 25.97 (3 x CH3), 21.46 (CH3), 18.37 (C), -4.59 (CH3), -
4.75 (CH3). 
(3S,4S,E)-4-(tert-Butyldimethylsilyloxy)-1-phenylpent-1-en-3-ol and (2S,3S,E)-3-(tert-butyldimethylsilyloxy)-
5-phenylpent-4-en-2-ol 
L-Selectride (1 M in THF; 20.4 mL, 20.4 mmol) was added dropwise over 30 minutes to a solution of (S,E)-4-(tert-
butyldimethylsilyloxy)-1-phenylpent-1-en-3-one (4.94 g, 17.0 mmol) in THF (100 mL) at -78 °C and the r eaction 
mixture was stirred for 3 h. TLC (light petroleum / EtOAc 95:5) indicated the consumption of starting material (Rf 
0.44) and the presence of two new compounds (Rf 0.24 and 0.18). The reaction mixture was partitioned with a 
mixture of EtOAc and water (1:1, 30 mL) and the phases then separated.  The organic layer was diluted with 
EtOAc (100 mL), washed with brine, dried with Na2SO4, filtered and evaporated to give a mixture 1:1.16 of 
(2S,3S,E)-3-(tert-butyldimethylsilyloxy)-5-phenylpent-4-en-2-ol and (3S,4S,E)-4-(tert-butyldimethyl-silyloxy)-1-
phenylpent-1-en-3-ol (7.69 g) as a colourless oil.  
(3S,4S)-4-(tert-Butyldimethylsilyloxy)-1-phenylpentan-3-ol 
A solution of (2S,3S,E)-3-(tert-butyldimethylsilyloxy)-5-phenylpent-4-en-2-ol and (3S,4S,E)-4-(tert-
butyldimethylsilyloxy)-1-phenylpent-1-en-3-ol (1:1.16 mixture; 4.97 g, 17.0 mmol) in ethanol (100 mL) was 
hydrogenated over 10% palladium on carbon (0.892 g) under hydrogen (1 atm) at 20 °C for 20 h.  TLC (li ght 
petroleum / EtOAc 95:5) indicated consumption of the starting materials and the presence of two new compounds 
(Rf 0.28 and 0.20).  The reaction mixture was flushed with nitrogen and filtered through celite, washing with EtOAc.  
                                                 
14
 G. Shapiro, D. Buechler and S. Hennet, Tetrahedron Lett., 1990, 31, 5733-5736. 
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The filtrate was concentrated in vacuo and the crude residue chromatographed on a silica gel column (80 g).  
Gradient elution with light petroleum / EtOAc (99:1~90:1) gave (3S,4S)-4-(tert-butyldimethylsilyloxy)-1-
phenylpentan-3-ol (Rf 0.28) (2.01 g, 6.83 mmol; 87%) and (2S,3S)-3-(tert-butyldimethylsilyloxy)-5-phenylpentan-2-
ol (Rf 0.20) (2.46 g, 8.35 mmol; 91%).  (3S,4S)-4-(tert-Butyldimethylsilyloxy)-1-phenylpentan-3-ol:  δH (400 MHz; 
CDCl3) 7.31 - 7.26 (2 H, m), 7.23 - 7.17 (3 H, m), 3.66 (1 H, qd, J 6.2 and 5.2, H-4), 3.33 - 3.29 (1 H, m, H-3), 2.91 - 
2.84 (1 H, m, H-1a), 2.74 - 2.66 (1 H, m, H-1b), 2.39 (1 H, br s), 1.78 - 1.66 (2 H, m, CH2-2), 1.18 (3 H, d, J 6.2), 
0.95 (9 H, s), 0.13 (6 H, s); δC (101 MHz; CDCl3) 142.31 (C), 128.49 (2 x CH), 128.35 (2 x CH), 125.74 (CH), 75.04 
(CH), 71.84 (CH), 35.35 (CH2), 32.13 (CH2), 25.85 (3 x CH3), 20.25 (CH3), 18.04 (C), -4.12 (SiCH3), -4.81 (SiCH3).  
(2S,3S)-3-(tert-Butyldimethylsilyloxy)-5-phenylpentan-2-ol:  δH (400 MHz; CDCl3) 7.35 - 7.30 (2 H, m), 7.25 - 7.20 (3 
H, m), 3.79 (1 H, qd, J 6.3 and 4.8, H-4), 3.56 (1 H, dt, J 6.0 and 4.8, H-3), 2.77 - 2.63 (2 H, m, CH2-1), 2.17 (1 H, 
br s, OH), 1.98 (1 H, ddt, J 13.9, 10.4 and 5.9, H-2a), 1.79 (1 H, dddd, J 4.8, 6.3, 11.0 and 13.9, H-2b), 1.21 (3 H, d, 
J 6.4), 0.97 (9 H, s), 0.14 (3 H, s), 0.13 (3 H, s); δC (101 MHz; CDCl3) 142.22 (C), 128.43 (2 x CH), 128.28 (2 x CH), 
125.84 (CH), 76.19 (CH), 68.98 (CH), 35.55 (CH2), 31.22 (CH2), 25.92 (3 x CH3), 19.56 (CH3), 18.15 (C), -4.13 
(SiCH3), -4.57 (SiCH3). 
9-[(3R,4S)-4-(tert-Butyldimethylsilyloxy)-1-phenylpentan-3-yl]-6-chloro-9H-purine 
Diisopropyl azodicarboxylate (2.52 mL, 12.8 mmol) was added to a stirred solution of (3S,4S)-4-(tert-
butyldimethylsilyloxy)-1-phenylpentan-3-ol (1.26 g, 4.27 mmol), 6-chloro-9H-purine (667 mg, 4.32 mmol) and 
triphenylphosphine (2.24 g, 8.54 mmol) in THF (100 mL) at room temperature and the mixture was stirred at room 
temperature for 48 h. TLC (3:1 light petroleum / EtOAc) indicated almost complete consumption of starting 
materials (Rf 0.74 and baseline) and formation of product (Rf 0.47).  The reaction mixture was filtered through a 
short silica gel column, washing with light petroleum / EtOAc (2:1, 150 mL), and the filtrate was concentrated in 
vacuo to give an orange oil (4.16 g) that was chromatographed on a silica gel column (80 g).  Gradient elution with 
light petroleum / EtOAc (9:1, 500 mL; 7:1, 800; 5:1, 540 mL) gave 9-[(3R,4S)-4-(tert-butyldimethylsilyloxy)-1-
phenylpentan-3-yl]-6-chloro-9H-purine (402 mg, 0.933 mmol; 22%) as a white solid:  δH (200 MHz; CDCl3) 8.70 (1 
H, s), 8.13 (1 H, s), 7.34 - 7.19 (3 H, m), 7.01 - 6.91 (2 H, m), 4.59 - 4.49 (1 H, m, chain H-3), 4.19 (1 H, qd, J 6.3 
and 4.4, chain H-4), 2.58 - 2.32 (4 H, m, chain CH2-1 and CH2-2), 1.11 (3 H, d, J 6.3, chain CH3-5), 0.84 (9 H, s), -
0.04 (3 H, s), -0.19 (3 H, s);  δC (50 MHz; CDCl3) 152.15 (C), 151.88 (CH), 151.13 (C), 145.19 (CH), 140.05 (C), 
131.77 (C), 128.73 (2 x CH), 128.34 (2 x CH), 126.57 (CH), 70.07 (CH), 61.89 (CH), 32.32 (CH2), 29.10 (CH2), 
25.95 (3 x CH3), 20.68 (CH3), 18.06 (C), -4.17 (SiCH3), -4.90 (SiCH3). 
9-[(3R,4S)-4-(tert-Butyldimethylsilyloxy]-1-phenylpentan-3-yl)-9H-purin-6-amine 
A mixture of 9-[(3R,4S)-4-(tert-butyldimethylsilyloxy)-1-phenylpentan-3-yl]-6-chloro-9H-purine (354 mg, 0.821 mmol) 
and ammonia (7 N in MeOH; 4.50 mL, 31.5 mmol) was heated at 80 °C in a sealed pressure tube for 18 h.  TLC 
(95:5 CH2Cl2 / MeOH) indicated consumption of starting material (Rf 0.81) and formation of two product 
components, minor (Rf 0.70) and major (Rf 0.40).  The reaction mixture was evaporated to give a crude white solid 
that was chromatographed on a silica gel column (40 g).  Gradient elution with CH2Cl2 / MeOH (99:1, 150 mL; 92:2, 
200 mL; 95:5, 150 mL) gave 9-[(3R,4S)-4-(tert-butyldimethylsilyloxy]-1-phenylpentan-3-yl)-9H-purin-6-amine (Rf 
0.40) (228 mg, 0.554 mmol; 67%) as a white solid and 9-[(3R,4S)-4-(tert-butyldimethylsilyloxy)-1-phenylpentan-3-
yl]-6-methoxy-9H-purine (Rf 0.70) (84 mg, 0.177 mmol; 22%) as a pale yellow dense oil. 
9-[(3R,4S)-4-(tert-Butyldimethylsilyloxy)-1-phenylpentan-3-yl]-9H-purin-6-amine:  δH (200 MHz; CDCl3) 8.34 (1 H, s), 
7.85 (1 H, s), 7.27 - 7.15 (3 H, m), 7.07 - 6.97 (2 H, m), 5.99 (2 H, br s, NH2), 4.44 - 4.34 (1 H, m, chain H-3), 4.13 
(1 H, qd, J 6.2 and 4.6, chain H-4), 2.52 - 2.33 (4 H, m, chain CH2-1 and CH2-2), 1.10 (3 H, d, J 6.2, chain CH3-5), 
0.85 (9 H, s), -0.05 (3 H, s), -0.20 (3 H, s);  δC (50 MHz; CDCl3) 155.68 (C), 152.93 (CH), 150.42 (C), 140.71 (CH), 
140.39 (C), 128.69 (2 x CH), 128.47 (2 x CH), 126.40 (CH), 120.13 (C), 70.21 (CH), 61.03 (CH), 32.33 (CH2), 
29.28 (CH2), 25.99 (3 x CH3), 20.94 (CH3), 17.84 (C), -4.16 (SiCH3), -4.95 (SiCH3). 
9-[(3R,4S)-4-(tert-Butyldimethylsilyloxy)-1-phenylpentan-3-yl]-6-methoxy-9H-purine:  δH (200 MHz; CDCl3) 8.52 (1 
H, s), 7.97 (1 H, br s), 7.23 - 7.12 (3 H, m), 7.02 - 6.91 (2 H, m), 4.49 - 4.35 (1 H, m, chain H-3), 4.18 (3 H, s, OMe), 
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4.12 (1 H, qd, J 6.2 and 4.7, chain H-4), 2.55 - 2.26 (4 H, m, chain CH2-1 and CH2-2), 1.07 (3 H, d, J 6.2, chain 
CH3-5), 0.83 (9 H, s), -0.07 (3 H, s), -0.21 (3 H, s);  δC (50 MHz; CDCl3) 161.19 (C), 151.97 (CH), 149.39 (C), 
141.98 (CH), 140.43 (C), 128.63 (2 x CH), 128.37 (2 x CH), 126.36 (CH), 121.73 (C), 70.08 (CH), 61.27 (CH), 
54.31 (OCH3), 32.20 (CH2), 29.27 (CH2), 25.91 (3 x CH3), 20.77 (CH3), 17.99 (C), -4.26 (SiCH3), -5.00 (SiCH3). 
(2S,3R)-3-(6-Amino-9H-purin-9-yl)-5-phenylpentan-2-ol 
Tetrabutylammonium fluoride (1 M in THF; 1.07 mL, 1.07 mmol) was added to a solution of 9-[(3R,4S)-4-(tert-
butyldimethylsilyloxy)-1-phenylpentan-3-yl]-9H-purin-6-amine (220 mg, 0.534 mmol) in THF (15 mL) at room 
temperature and stirred for 18 h. TLC (95:5 CH2Cl2 / MeOH) indicated consumption of starting material (Rf 0.40) 
and formation of a product component (Rf 0.26).  The reaction mixture was evaporated and the residue was 
dissolved in EtOAc (50 mL), washed with brine (3 x 10 mL), dried over Na2SO4, filtered and concentrated in vacuo 
to give a crude white solid. The crude material was chromatographed on a silica gel column (15 g).  Gradient 
elution with CH2Cl2 / MeOH (98:2, 150 mL; 95:5, 200 mL; 9:1, 150 mL) gave (2S,3R)-3-(6-amino-9H-purin-9-yl)-5-
phenylpentan-2-ol (Rf 0.26) (150 mg, 0.504 mmol; 94%) as a dense colourless oil that solidified upon standing:  δH 
(200 MHz; CDCl3) 8.26 (1 H, br s), 7.76 (1 H, br s), 7.23 - 7.12 (3 H, m), 7.02 (2 H, ~d, J 7.6), 6.50 (2 H, s, NH2), 
5.55 (1 H, br s, OH), 4.31 - 4.13 (2 H, m, chain H-2 and H-3), 2.56 - 2.21 (4 H, m, chain CH2-4 and CH2-5), 1.22 (3 
H, d, J 6.3, chain CH3-1);  δC (50 MHz; CDCl3) 156.02 (C), 152.54 (CH), 149.77 (C), 140.71 (CH), 140.28 (C), 
128.72 (2 x CH), 128.41 (2 x CH), 126.47 (CH), 120.19 (C), 69.61 (CH), 62.45 (CH), 32.21 (CH2), 28.72 (CH2), 
20.32 (CH3).  (2S,3R)-3-(6-Amino-9H-purin-9-yl)-5-phenylpentan-2-ol was evaluated as its hydrochloride salt, 
formed by treatment with a solution of hydrogen chloride in ether followed by evaporation: (found: C, 52.47; H, 5.84; 
N, 18.97. C16H19N5O/1.9 HCl requires C, 52.42; H, 5.75; N, 19.10%). 
(rac)-9-(nonan-3-yl)-9H-purin-6-amine (HWC-57) 
(rac)-6-Chloro-9-(nonan-3-yl)-9H-purine 
Diisopropyl azodicarboxylate (2.33 mL, 12.0 mmol) was added to a mixture of nonan-3-ol (1.26 mL, 7.20 mmol), 6-
chloro-9H-purine (0.93 g, 6.00 mmol) and triphenylphosphine (2.36 g, 9.00 mmol) in THF (50 mL) at room 
temperature and stirred for 48 h.  TLC (4:1 light petroleum / EtOAc) indicated consumption of nonan-3-ol (Rf 0.59) 
and formation of a product component (Rf 0.28).  The reaction mixture was filtered through a short silica gel column, 
washing with light petroleum / EtOAc (1:1, 100 mL).  Evaporation of the filtrate gave a crude yellow oil that was 
chromatographed on a silica gel column (80 g).  Gradient elution with light petroleum / EtOAc (9:1, 1 L; 7:1, 800 mL; 
5:1, 840 mL) gave 6-chloro-9-(nonan-3-yl)-9H-purine (1.30 g, 4.63 mmol; 77%) as a dense pale yellow oil:  δH (200 
MHz; CDCl3): 8.70 (1 H, s), 8.08 (1 H, s), 4.47 (1 H, m), 2.07 - 1.88 (4 H, m), 1.27 - 1.10 (8 H, m), 0.83 - 0.72 (6 H, 
m);  δC (50 MHz; CDCl3): 152.25 (C), 151.88 (CH), 151.14 (C), 144.15 (CH), 131.91 (C), 59.01 (CH), 34.75 (CH2), 
31.65 (CH2), 28.90 (CH2), 28.29 (CH2), 26.23 (CH2), 22.63 (CH2), 14.15 (CH3), 10.84 (CH3). 
(rac)-9-(Nonan-3-yl)-9H-purin-6-amine (HWC-57) 
A mixture of 6-chloro-9-(nonan-3-yl)-9H-purine (560 mg, 1.99 mmol) and ammonia (7 N in MeOH; 4.5 mL, 31 mmol) 
was heated at 80 °C in a 5 mL sealed pressure tube for 18 h.  TLC (1:1 light petroleum / EtOAc) indicated 
remaining starting material (Rf 0.66) and two new product components, minor (Rf 0.41) and major (Rf 0.06). The 
reaction mixture was evaporated to give a crude white solid that was chromatographed on a silica gel column (20 
g).  Gradient elution with light petroleum / EtOAc (4:1, 400 mL; 1:1, 200 mL) followed by CH2Cl2 / MeOH (9:1, 100 
mL) gave starting material 6-chloro-9-(nonan-3-yl)-9H-purine (287 mg) and 9-(nonan-3-yl)-9H-purin-6-amine (Rf 
0.06) (145 mg, 0.56 mmol; 28%) as a white solid:  δH (200 MHz; CDCl3) 8.30 (1 H, s), 7.76 (1 H, s), 6.33 (2 H, br s), 
4.59 - 4.41 (1 H, m), 2.02 - 1.80 (4 H, m), 1.27 - 1.03 (8 H, m), 0.86 - 0.69 (6 H, m);  δC (50 MHz; CDCl3) 155.89 (C), 
152.84 (CH), 150.47 (C), 139.21 (CH), 119.87 (C), 57.88 (CH), 34.94 (CH2), 31.70 (CH2), 28.98 (CH2), 28.45 (CH2), 
26.22 (CH2), 22.64 (CH2), 14.16 (CH3), 10.81 (CH3). 9-(Nonan-3-yl)-9H-purin-6-amine was evaluated as its 
hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether followed by evaporation: 
(found: C, 51.03; H, 7.76; N, 21.25. C14H23N5/1.87 HCl requires C, 51.02; H, 7.61; N, 21.34%). 
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(2S,3S)-3-(6-amino-9H-purin-9-yl)hexan-2-ol (HWC-60) 
(S,E)-2-(tert-Butyldimethylsilyloxy)hex-4-en-3-one  
Lithium chloride (0.69 g, 16.2 mmol) was added to a solution of (S)-dimethyl 3-(tert-butyldimethylsilyloxy)-2-
oxobutylphosphonate14 (5.03 g, 16.2 mmol) in acetonitrile (100 mL) under argon at room temperature.  N,N-
Diisoproplyethylamine (2.41 mL, 13.4 mmol) was added and the reaction mixture was stirred for 2 h to give a 
viscous mixture.  Acetaldehyde (0.99 mL, 17.2 mmol) was added and the reaction mixture was stirred for a further 
92 h.  TLC (10% EtOAc / light petroleum) indicated a new component (Rf 0.52).  The reaction mixture was 
quenched with brine (50 mL), extracted with EtOAc (3 x 40 mL), dried with Na2SO4 and evaporated to give a crude 
colourless oil (2 g).  The crude material was chromatographed on a silica gel column (40 g).  Elution with 2% 
EtOAc / light petroleum gave (S,E)-2-(tert-butyldimethylsilyloxy)hex-4-en-3-one (1.92 g, 8.40 mmol; 52%): δH (200 
MHz; CDCl3) 6.99 (1 H, dq, J 15.6 & 6.9), 6.57 (1 H, dt, J 15.5 & 1.6), 4.22 (1 H, q, J 6.8), 1.89 (3 H, dd, J 6.8 & 
1.6), 1.27 (3 H, d, J 6.8), 0.88 (9 H, s), 0.04 (6 H, s);  dC (50 MHz; CDCl3) 201.91 (CO), 144.35 (CH), 125.88 (CH), 
74.50 (CH), 25.91 (3 x CH3), 21.30 (CH3), 18.70 (CH3), 18.33 (C), -4.69 (SiCH3), -4.83 (SiCH3). 
(2S,3S,E)-2-(tert-Butyldimethylsilyloxy)hex-4-en-3-ol and 
(2S,3S,E)-3-(tert-butyldimethylsilyloxy)hex-4-en-2-ol 
Lithium tri-sec-butylborohydride (1 M THF solution; 11.2 mL, 11.2 mmol) was added dropwise to a solution of (S,E)-
2-(tert-butyldimethylsilyloxy)hex-4-en-3-one (1.71 g, 7.50 mmol) in THF (40 mL) under argon at 0 °C over a pe riod 
of 15 minutes and the reaction mixture was stirred for a further 3 h.  TLC (5% EtOAc / light petroleum) indicated 
formation of a new component (Rf 0.29).  The reaction mixture was quenched by the slow addition of a mixture of 
EtOAc / water (1:1, 20 mL).  The organic layer was washed with brine (2 x 10 mL), dried with Na2SO4 and 
evaporated to give a pale brown oil.  The crude oil was chromatographed on a silica gel column (30 g).  Elution with 
2% EtOAc / light petroleum gave a mixture of (2S,3S,E)-2-(tert-butyldimethylsilyloxy)hex-4-en-3-ol and (2S,3S,E)-
3-(tert-butyldimethylsilyloxy)hex-4-en-2-ol (1.70 g, 7.38 mmol; 98%) that was taken forward in the hydrogenation 
step detailed below. 
9-[(2S,3R)-2-(tert-Butyldimethylsilyloxy)hexan-3-yl]-6-chloro-9H-purine 
10% Palladium on charcoal (100 mg) was added to a mixture of (2S,3S,E)-2-(tert-butyldimethylsilyloxy)hex-4-en-3-
ol and (2S,3S,E)-3-(tert-butyldimethylsilyloxy)hex-4-en-2-ol (1.68 g, 7.29 mmol) dissolved in ethanol (20 mL).  The 
mixture was hydrogenated for 18 h at room temperature under hydrogen (1 atm).  TLC (5% EtOAc / light petroleum) 
indicated consumption of starting material and the reaction mixture was filtered, washing with ethanol (2 x 30 mL).  
The filtrate was concentrated in vacuo to give a mixture of crude (2S,3S)-2-(tert-butyldimethylsilyloxy)hexan-3-ol 
and (2S,3S)-3-(tert-butyldimethylsilyloxy)hexan-2-ol (1.43 g). To a solution of this mixture in THF (50 mL) was 
added diisopropyl azodicarboxylate (2.51 mL, 12.9 mmol), triphenylphosphine (2.54 g, 9.68 mmol) and 6-chloro-
9H-purine (1.30 g, 8.39 mmol). After 18 h at room temperature the reaction mixture was filtered through a short 
silica pad, washing with petroleum / EtOAc (3:1, 100 mL).  The filtrate was evaporated at reduced pressure to give 
a crude oil that was chromatographed on a silica gel column (80 g).  Gradient elution with light petroleum (100 mL) 
followed by light petroleum / EtOAc (98:2, 200 mL; 96:4, 100 mL; 94:6, 100 mL; 92:8, 100 mL) gave 9-[(2S,3R)-2-
(tert-butyldimethylsilyloxy)hexan-3-yl]-6-chloro-9H-purine (251 mg, 0.68 mmol) and 9-[(2S,3S)-3-(tert-
butyldimethylsilyloxy)hexan-2-yl]-6-chloro-9H-purine (171 mg, 0.46 mmol).  9-[(2S,3R)-2-(tert-Butyldimethyl-
silyloxy)hexan-3-yl]-6-chloro-9H-purine: δH (200 MHz; CDCl3) 8.71 (1 H, s), 8.17 (1 H, s), 4.56 (1 H, dt, J 11.4 & 4.0, 
chain H-3), 4.10 (1 H, qd, J 6.2 & 4.1, chain H-2), 2.24 - 1.89 (2 H, m), 1.21 - 0.99 (2 H, m), 1.18 (3 H, d, J 6.3), 
0.87 (3 H, t, J 6.5), 0.86 (9 H, s), -0.02 (3 H, s), -0.19 (3 H, s).  9-[(2R,3S)-3-(tert-Butyldimethylsilyloxy)hexan-2-yl]-
6-chloro-9H-purine: δH (200 MHz; CDCl3) 8.73 (1 H, s), 8.18 (1 H, s), 4.88 (1 H, qd, J 7.1 & 3.1, chain H-2), 4.02 - 
3.94 (1 H, m, chain H-3), 1.61 (3 H, d, J 7.1), 1.61 - 0.13 (4 H, m), 0.98 (3 H, t, J 6.5), 0.84 (9 H, s), -0.09 (3 H, s), -
0.51 (3 H, s). 
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9-[(2S,3R)-2-(tert-Butyldimethylsilyloxy)hexan-3-yl]-9H-purin-6-amine  
A mixture of 9-[(2S,3R)-2-(tert-butyldimethylsilyloxy)hexan-3-yl]-6-chloro-9H-purine (251 mg, 0.68 mmol) in 
aqueous ammonia (SG 0.880; 3.0 mL) was heated at 100 °C in a sealed tube for 18 h.  TLC (5% MeOH / CH 2Cl2) 
indicated formation of a new component (Rf 0.24).  The reaction mixture was cooled and extracted with EtOAc (3 x 
20 mL).  The combined organic extracts were washed with brine (15 mL), dried with Na2SO4 and evaporated under 
reduced pressure to give a crude white solid that was chromatographed on a silica gel column (20 g).  Gradient 
elution with CH2Cl2 (100 mL); followed by CH2Cl2 / MeOH (99:1, 100 mL; 98:2, 100 mL; 97:3, 100 mL) gave 9-
[(2S,3R)-2-(tert-butyldimethylsilyloxy)hexan-3-yl]-9H-purin-6-amine (186 mg, 0.53 mmol; 78%): δH (200 MHz; 
CDCl3) 8.35 (1 H, s), 7.86 (1 H, s), 5.69 (2 H, br s), 4.45 (1 H, dt, J 11.2 & 4.3, chain H-3), 4.11 (1 H, qd, J 6.3 & 4.1, 
chain H-2), 2.20 - 1.87 (2 H, m), 1.19 - 1.04 (2 H, m), 1.17 (3 H, d, J 6.3), 0.88 (3 H, t, J 6.5), 0.88 (9 H, s), -0.02 (3 
H, s), -0.19 (3 H, s).  
(2S,3R)-3-(6-Amino-9H-purin-9-yl)hexan-2-ol (HWC-60) 
Tetrabutylammonium fluoride (1 M THF solution; 1.03 mL, 1.03 mmol) was added to a solution of 9-[(2S,3R)-2-
(tert-butyldimethylsilyloxy)hexan-3-yl]-9H-purin-6-amine (180 mg, 0.52 mmol) in THF (10 mL) at room temperature 
and stirred for 18 h.  TLC (1:1 EtOAc / acetone) indicated consumption of starting material (Rf 0.64) and formation 
of a product component (Rf 0.26).  The reaction mixture was evaporated to give a crude residue that was dissolved 
in EtOAc (50 mL), washed with brine (3 x 10 mL), dried with Na2SO4, filtered and concentrated in vacuo to give a 
crude oil.  The crude material was chromatographed on a silica gel column (15 g).  Gradient elution with CH2Cl2 / 
MeOH (98:2, 250 mL; 95:5, 300 mL) gave partially purified (2S,3R)-3-(6-amino-9H-purin-9-yl)hexan-2-ol (Rf 0.26, 
116 mg) as a colourless oil. The partially purified material was re-chromatographed on a silica gel column (15 g). 
Gradient elution with EtOAc / acetone (1.5:1, 250 mL; 1:1, 200 mL) gave (2S,3R)-3-(6-amino-9H-purin-9-yl)hexan-
2-ol (Rf 0.26) (67 mg, 0.29 mmol; 55%) as a white amorphous solid:  δH (200 MHz; CDCl3) 8.22 (1 H, s), 7.83 (1 H, 
s), 6.81 (2 H, br s), 5.72 (1 H, br s), 4.35 (1 H, dt, J 11.0 & 3.2), 4.18 (1 H, qd, J 6.5 & 2.9, chain H-2), 2.15 - 1.77 (2 
H, m), 1.22 (3 H, d, J 7.1), 1.22 - 0.98 (2 H, m), 0.81 (3 H, t, J 7.2);  δC (50 MHz; CDCl3) 156.10 (C), 152.51 (CH), 
149.84 (C), 140.35 (CH), 119.64 (C), 69.37 (CH), 62.39 (CH), 29.71 (CH2), 20.23 (CH3), 19.48 (CH2), 13.71 (CH3); 
(found: C, 55.26; H, 7.30; N, 28.79. C11H17N5O/0.29 H2O requires C, 54.93; H, 7.37; N, 29.12%). 
(rac)-9-(octan-3-yl)-9H-purin-6-amine (HWC-62) 
(rac)-6-Chloro-9-(octan-3-yl)-9H-purine 
Diisopropyl azodicarboxylate (1.50 mL, 8.00 mmol) was added to a stirred mixture of octan-3-ol (0.76 mL, 4.8 
mmol), 6-chloro-9H-purine (618 mg, 4.00 mmol) and triphenylphosphine (1.60 g, 6.00 mmol) in THF (30 mL) at 
room temperature. After 18 h TLC (80% light petroleum / EtOAc) indicated formation of a product component (Rf 
0.35).  The reaction mixture was concentrated in vacuo and filtered through a short silica gel column, washing with 
light petroleum / EtOAc (1:1).  Evaporation of the filtrate gave a crude yellow oil that was chromatographed on a 
silica gel column (60 g).  Elution with light petroleum / EtOAc (9:1, 1 L; 7:1, 800 mL) gave 6-chloro-9-(decan-3-yl)-
9H-purine (825 mg, 3.10 mmol; 77%) as a dense yellow oil:  δH (200 MHz; CDCl3) 8.71 (1 H, s), 8.09 (1 H, s), 4.56 
- 4.41 (1 H, m), 2.11 - 1.81 (4 H, m), 1.33 - 0.95 (6 H, m), 0.82 - 0.75 (6 H, m);  δC (50 MHz; CDCl3) 152.19 (C), 
151.80 (CH), 151.08 (C), 144.08 (CH), 131.85 (C), 59.96 (CH), 34.61 (CH2), 31.30 (CH2), 28.19 (CH2), 25.86 (CH2), 
22.42 (CH2), 13.96 (CH3), 10.73 (CH3). 
(rac)-9-(Octan-3-yl)-9H-purin-6-amine (HWC-62) 
A mixture of 6-chloro-9-(octan-3-yl)-9H-purine (323 mg, 1.21 mmol) and aqueous ammonia (SG 0.880; 4.5 mL) 
was heated at 100 °C in a 5 mL sealed pressure tube  for 18 h.  TLC (95:5 CH2Cl2 / MeOH) indicated conversion of 
starting material (Rf 0.72) into product (Rf 0.22).  The reaction mixture was evaporated to give a crude waxy solid 
that was chromatographed on a silica gel column (15 g).  Elution with CH2Cl2 / MeOH (95:5, 100 mL) gave 9-
(octan-3-yl)-9H-purin-6-amine (Rf 0.22) (286 mg, 1.16 mmol; 96%) as a pale yellow solid:  δH (200 MHz; CDCl3) 
Burton et al  Supplementary Material 
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8.31 (1 H, s), 7.62 (1 H, s), 6.51 (2 H, br s), 4.45 - 4.31 (1 H, m), 2.04 - 1.75 (4 H, m), 1.29 - 0.95 (6 H, m), 0.77 (6 
H, t, J 7.3);  δC (50 MHz; CDCl3) 155.95 (C), 152.79 (CH), 150.39 (C), 139.06 (CH), 119.83 (C), 57.76 (CH), 34.77 
(CH2), 31.37 (CH2), 28.32 (CH2), 25.83 (CH2), 22.44 (CH2), 13.97 (CH3), 10.69 (CH3).  9-(Octan-3-yl)-9H-purin-6-
amine was evaluated as its hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether 
followed by evaporation: (found: C, 49.22; H, 7.81; N, 21.64. C13H21N5/1.63 HCl/0.70 H2O requires C, 48.89; H, 
7.58; N, 21.93%). 
Procedure for the preparation of 9-(decan-1-yl)-9H-purin-6-amine (HWC-64) 
6-Chloro-9-(decan-1-yl)-9H-purine 
Diisopropyl azodicarboxylate (1.8 mL, 9.3 mmol) was added to a stirred solution of decan-1-ol (1.1 g, 6.9 mmol), 6-
chloro-9H-purine (720 mg, 4.66 mmol) and triphenylphosphine (1.8 g, 6.9 mmol) in THF (30 mL) at ambient 
temperature.  After 18 h TLC (9:1 light petroleum / EtOAc) indicated formation of a product component (Rf 0.2).  
The reaction mixture was filtered through a short silica gel column, washing with light petroleum / EtOAc (1:1).  The 
filtrate was evaporated and the resulting red oil was chromatographed on flash silica gel (gradient elution with 15-
20% EtOAc / light petroleum) to give 6-chloro-9-(decan-1-yl)-9H-purine (1.30 g, 4.41 mmol; 96%) as a pale brown 
powder: δH 8.74 (1 H, s), 8.11 (1 H, s), 4.28 (2 H, t, J 7.2), 1.92 (2 H, ~quintet, J 7.0), 1.41 - 1.13 (14 H, m), 0.6 (3 
H, ~t, J 6.4). 
9-(Decan-1-yl)-9H-purin-6-amine (HWC-64) 
A mixture of 6-chloro-9-(decan-1-yl)-9H-purine (300 mg, 1.02 mmol) and aqueous ammonia (SG 0.880; 3 mL) was 
heated at 100 °C in a 5 mL sealed pressure tube for  18 h.  TLC (2% MeOH / CH2Cl2) indicated conversion of 
starting material (Rf 0.45) to a product component (Rf 0.1).  The reaction mixture was extracted with EtOAc; the 
extract was washed with saturated brine, dried (Na2SO4) and evaporated.  The resulting crude white solid (282 mg) 
was chromatographed on a silica gel column.  Elution with 2% MeOH / CH2Cl2 gave 9-(decan-1-yl)-9H-purin-6-
amine (203 mg, 0.737 mmol; 72%) as a white solid:  δH (200 MHz; CDCl3) 8.35 (1 H, s), 7.78 (1 H, s), 6.32 (2 H, br 
s), 4.16 (2 H, t, J 7.1), 1.86 (2 H, ~quintet, J 6.5), 1.40 - 1.15 (14 H, m), 0.88 (3 H, ~t, J 6.9);  δC (101 MHz, CDCl3) 
155.73 (C), 152.91 (CH), 150.07 (C), 140.32 (CH), 119.68 (C), 43.95 (CH2), 31.82 (CH2), 30.08 (CH2), 29.43 (CH2), 
29.40 (CH2), 29.21 (CH2), 29.03 (CH2), 26.65 (CH2), 22.63 (CH2), 14.08 (CH3).  9-(Decan-1-yl)-9H-purin-6-amine 
was evaluated as its hydrochloride salt, formed by treatment with a solution of hydrogen chloride in ether followed 
by evaporation: (found: C, 56.83; H, 8.39; N, 22.06. C15H25N5/1.15 HCl requires C, 56.78; H, 8.31; N, 22.06%). 
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Supplementary Figure 1. EHNA inhibits 
differentiation to mesoderm (a), ectoderm (b), 
endoderm (c) or trophectoderm (d) over 
multiple passages in the absence of FGF. 
Analysis of mRNA from cells passaged to p8 
in standard feeder free media (FF,   ), without 
exogenous FGF but supplemented with 10µM 
EHNA (No FGF/+EHNA media (NFE,   ) and 
standard feeder free conditions without 
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expression is relative to GAPDH expression
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Supplementary Figure 2. Standard hESC expression profile is maintained by EHNA in the absence of 
FGF for up to 30 passages. Analysis of mRNA from cells passaged in standard feeder free media (FF) or 
standard feeder free conditions without exogenous FGF but supplemented with 10 µM EHNA (NFE). Gene 
expression is relative to GAPDH expression. The phase image is of hESCs grown in EHNA (NFE) for 30 
passages post FGF withdrawl.
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Supplementary Figure 3.  Cells grown with EHNA in the absence of exogenous FGF can differentiate into 
cells expressing markers of all three germ layers after at least 22 passages. After growth for 22 passages in the 
presence of EHNA instead of FGF hESCs were transferred to matrigel coated dishes or formed into embryoid 
bodies, and differentiated for 4 weeks in 20% fetal calf serum. Immunostaining for beta tubulin III (ectoderm), PAX6 
(ectoderm), smooth muscle actin (SMA) (mesoderm) and AFP (endoderm). Specific antibodies are in either green or 
red and all cells were also stained with DAPI (blue). Magnification x10.
Supplementary Figure 4.  Structures of compounds tested for hESC maintenance effect. †The solubility HWC-04 and HWC-
32 (even in hydrochloride form) was poor, precluding assessment of these compounds. *Cladribine and 2-fluoroadenosine, 
nucleoside analogues with modest ADA-inhibitory activity, showed no activity at sub-toxic concentrations (10 µM); their toxicity to 
hESCs precluded assessment at higher concentrations.
OH
N
N
NHMe
N
N
N N
N
OH
(rac)-
N
N N
N
NH2
(CH2)9CH3
N
NN
H
O
OH
HWC-05 HWC-06 HWC-07 HWC-08 HWC-09
OH OH
N
N
N N
NH2
N
N
(rac)- (rac)- (rac)-
HWC-10
OH
N
N
Cl
N
N
(rac)-
HWC-12
OH
N
N N
N
(rac)-
HWC-13
OH
N
N
SH
N
N
(rac)-
HWC-14
OH
N
N
OH
N
N
(rac)-
HWC-16 HWC-17 HWC-18
N6-methyladenosine
HWC-19*
cladribine
HWC-20*
2-fluoroadenosine
HWC-21
fludarabine
HWC-24 HWC-25 HWC-26
(rac)-
OH
N
N
NMe2
N
N
(rac)- HO
N
NN
N
NHMe
O
OHOH
N
NN
N
NH2
Cl
N
NN
N
NH2
F
N
NN
N
NH2
FHO O
OH
HO
O
OHOH
HO
O OH
OH OH
N
N
NH2
N
N
(rac)-
OH
N
N
SMe
N
N
(rac)-
OH
N
N
NH2
N
N
N(rac)-
HO
O
HO
N
N OH
NHN
N
N N
N
NH2
HWC-04 
(CH2)9CH3
OH
N
N
OMe
N
N
HWC-15
(rac)-
HWC-30 HWC-31 HWC-32 HWC-33 HWC-34 HWC-35 HWC-36HWC-27
OH
N
N
NHNH2
N
N
(rac)-
pentostatin
(deoxycoformycin)
OH
N
N
NH2
N
N
(rac)-
EHNA
N
N N
N
NH2
(CH2)8CH3
N
N N
N
NH2
(CH2)8CH3 N
N N
N
NH2
(CH2)10CH3
N
N N
N
NH2
(CH2)10CH3
N
NH2N
O
OH
(rac)-N
N N
N
NH2
N
N N
N
NH2
O
O
OMe
OMe
N
N N
N
NH2
(CH2)7CH3
HWC-41
HWC-44 HWC-46
(+)-EHNA
N
N N
N
NH2
HWC-40
(CH2)7CH3
OHPh
N
N
NH2
N
N
(abs)-
OH
N
N
NH2
N
N
(abs)-
HWC-52
(-)-EHNA
HWC-57 HWC-60
OH
N
N
NH2
N
N
(abs)- N
N
NH2
N
N
(rac)-
OH
N
N
NH2
N
N
(abs)-
HWC-62 HWC-64
N
N
NH2
N
N
(rac)-
(abs)-
N
N
NH2
N
N
05
10
15
20
25
30
CO
N
EH
NA
HW
C-0
6
HW
C-0
7
HW
C-0
8
HW
C-0
9
HW
C-1
0
HW
C-1
2
HW
C-1
3
HW
C-1
4
HW
C-1
5
HW
C-1
6
HW
C-1
7
HW
C-1
8
HW
C-2
1
HW
C-2
4
R
e
la
tiv
e
 
Ex
pr
e
ss
io
n
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
CO
N
EH
NA
HW
C-0
6
HW
C-0
7
HW
C-0
8
HW
C-0
9
HW
C-1
0
HW
C-1
2
HW
C-1
3
HW
C-1
4
HW
C-1
5
HW
C-1
6
HW
C-1
7
HW
C-1
8
HW
C-2
1
HW
C-2
4
R
e
la
tiv
e
 
Ex
pr
e
ss
io
n
Supplementary Figure 5. Summary of the HWC data.  hESCs were plated onto matrigel
coated 12 well dishes and differentiated for 14 days in defined media (with and without 
compound addition) then harvested and analysed by qRT-PCR. Compounds and media were 
changed every 2 days. Data represents mean ± SEM from three experiments. Expression is 
relative to expression in the untreated control samples. Each section of the figure represents a 
separate experiment hence the need for separate controls. (a) HWC-06 – HWC-24
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Supplementary Figure 5b.  HWC-25 – HWC-36
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Supplementary Figure 5c.  HWC-40 – HWC-52
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Supplementary Figure 5d. HWC-57 – HWC-60
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Supplementary Figure 5e. HWC-62 – HWC-64
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Supplementary Figure 6.  EHNA does not have inhibitory activity against a panel of 
common kinases.
Kinase screen of EHNA, pentostatin, HWC-05 and HWC-06 all assayed at 30 µM
Supplementary Figure 7.  Cells maintained in EHNA, HWC57 or HWC64 
maintain a normal karyotype. A minimum of 15 cells were examined. This 
excludes greater than 19% mosaicism with 95% confidence limits. Analysis 
performed by the Cytogenetics Laboratory, Institute of Medical Genetics, Yorkhill
Hospital, Glasgow.
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